 

 

 

 Review

(cid:3)(cid:3)AGING, (cid:48)(cid:68)(cid:85)(cid:70)(cid:75) 20(cid:20)(cid:20), Vol. (cid:22). No(cid:17) (cid:22)
 

  www.impactaging.com
 
 
 
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways 
in  controlling  growth  and  sensitivity  to  therapy-implications  for
cancer and aging  
 
Linda S. Steelman1,2, William H. Chappell1, Stephen L. Abrams1, C. Ruth Kempf2,  
Jacquelyn Long2, Piotr Laidler3, Sanja Mijatovic4, Danijela Maksimovic‐Ivanic4,  
Franca  Stivala5,  Maria  C.  Mazzarino5,  Marco  Donia5,  Paolo  Fagone5,  Graziella  Malaponte5, 
Ferdinando  Nicoletti5,  Massimo  Libra5,   Michele  Milella6,  Agostino  Tafuri7,  Antonio  Bonati8, 
Jörg Bäsecke9, Lucio Cocco10, Camilla Evangelisti10, Alberto M. Martelli10,11,  
Giuseppe Montalto12, Melchiorre Cervello13 and James A. McCubrey1 
 
1Department of Microbiology and Immunology, 2Department of Physics, East Carolina University, Greenville, NC 
27858, USA 
3Department of Medical Biochemistry, Jagiellonian University Medical College, Krakow, Poland  
4Department of Immunology, Instititue for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, 
Serbia 
5Department of Biomedical Sciences, University of Catania, Catania, Italy 
6Regina Elena Cancer Center,Rome 00144, Italy 
7University of Rome, La Sapienza, Department of Hematology‐Oncology, Rome 99161, Italy 
8University Hospital of Parma, Unit of Hematology and Bone‐Marrow Transplantation, Via Gramsi n.14, Parma 
43100, Italy 
9Department of Medicine, University of Göttingen, Göttingen, Germany 
10Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell’Apparato Locomotore, Università di Bologna, 
Bologna, Italy 
11IGM‐CNR, Sezione di Bologna, C/o IOR, Bologna, Italy 
12Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy 
13Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia, Molecolare"Alberto Monroy", Palermo, 
Italy 
 
Key words: Raf, MEK, PI3K, mTOR, cancer, kinases, protein phosphorylation, signal transduction, apoptosis 
Received: 2/25/11; Accepted: 3/10/11; Published: 3/10/11 
Corresponding author: James A. McCubrey, PhD;  Email: mccubreyj@ecu.edu 
 
© Steelman et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
 
Abstract:  Dysregulated  signaling  through  the  Ras/Raf/MEK/ERK  and  PI3K/PTEN/Akt/mTOR  pathways  is  often  the  result  of
genetic  alterations  in  critical  components  in  these  pathways  or  upstream  activators.  Unrestricted cellular proliferation  and
decreased sensitivity to apoptotic‐inducing agents are typically associated with activation of these pro‐survival pathways. This 
review  discusses  the  functions  these  pathways  have  in  normal  and  neoplastic  tissue  growth  and  how  they  contribute  to
resistance  to  apoptotic  stimuli.  Crosstalk  and  commonly  identified  mutations  that  occur  within  these  pathways  that
contribute  to  abnormal  activation  and  cancer  growth  will  also  be  addressed.  Finally  the  recently  described  roles  of  these
pathways in cancer stem cells, cellular senescence and aging will be evaluated. Controlling the expression of these pathways
could ameliorate human health.  
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
www.impactaging.com 

 

 

 

          192                                          AGING,  March 2011, Vol.3 No.3

 

INTRODUCTION 
 
The  Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/ 
mTOR  signaling  pathways  have  been  shown  over  the 
past  25  years  to  play  key  roles  in  the  transmission  of 
proliferative  signals  from  membrane  bound  receptors. 
Mutations  can  occur  in  the  genes  encoding  pathway 
constituents  (e.g.,  RAS,  RAF,  PIK3CA,  PTEN,  AKT, 
TSC1,  TSC2)  or  in  upstream  receptors  which  activate 
these pathways. These pathways relay this information 
through  interactions  with  various  other  proteins  to  the 
nucleus to control gene expression [1-13]. This review 
will  discuss  how  these  pathways  may  be  aberrantly 
regulated by either upstream mutations/amplification or 
by  intrinsic  mutations  of  key  components  of  these 
signaling  pathways.  Elevated 
levels  of  activated 
components of these pathways are often associated with 
poor prognosis in cancer patients or premature aging [2-
5,  7].  Increased  expression  of  signaling  pathways  can 
also  be  correlated  with  altered  sensitivity  to  targeted 
therapy  compared  to  patients  that  do  not  exhibit 
elevated  expression  [2-4].  Inhibition  of  Raf,  MEK, 
PI3K,  Akt  and  mTOR  may  prove  useful  in  cancer 
treatment  as  well  as  in  preventing  or  suppressing 
cellular  aging.  These  observations  have  propelled  the 
pharmaceutical industry to develop inhibitors that target 
key components of these pathways. 
 
 The  Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/ 
mTOR  signaling  pathways  consist  of  kinases  cascades 
that  are 
regulated  by  phosphorylation  and  de-
phosphorylation  by  specific  kinases,  phosphatases  as 
well  as  GTP/GDP  exchange  proteins,  adaptor  proteins 
and  scaffolding  proteins.  The  regulation  of  these 
cascades  can  be  much  like  the  axiom  of  real  estate, 
“location-location-location”, 
the  membrane 
localization  of  these  components  is  often  critical  for 
their  activity,  even  though  some  members  of  these 
pathways  can  function  in  other  cellular  regions  (e.g., 
mitochondrion,  nucleus). 
emerging 
observation in both extracellular signal-regulated kinase 
1 and 2 (ERK1/2) and mammalian target of rapamycin 
(mTOR)  signaling  is  the  realization  that  pathways 
generate  specific  biological  responses  dependent  upon 
where  in  the  cell  the  signal  originates  [12].  For 
example,  phosphorylation  of  both  epidermal  growth 
factor  receptor  (EGFR)  and  cytosolic  phospholipase 
A(2)  [cPLA(2)]  is  most  prominent  when  ERK1/2  is 
activated  from  lipid  rafts,  whereas  p90  Ribosomal  S6 
kinase-1  (p90Rsk-1)  is  mainly  activated  by  Ras  signals 
emanating  from  disordered  membranes.  This  substrate 
selectivity is governed by the participation of different 
scaffold  proteins  that  distinctively  couple  ERK1/2, 
activated  at  defined  subcellular  domains,  to  specific 
substrates.  Ras  subcellular  localization  can  determine 

Indeed,  one 

as 

reference  point 

substrate  specificity  through  distinct  utilization  of 
scaffold  proteins  [1,6,12].  Clearly 
the  subcellular 
localization of pathway components and the presence of 
various  adaptor  and  scaffolding  molecules  are  critical 
for  the  activity  of  these  pathways.  The  regulation  and 
function  of  these  two  pathways  will  be  concisely 
reviewed as well as the effects of genetic mutations that 
are important in human cancer. 
 
The Ras/Raf/MEK/ERK Pathway 
 
An  introductory  overview  of  the  Ras/Raf/MEK/ERK 
pathway is presented in Figure 1. Also outlined in this 
figure  are  common  sites  of  intervention  with  signal 
transduction  inhibitors.  Many  of  these  inhibitors  have 
been  evaluated  in  various  clinical  trials  and  some  are 
currently  being  used  to  treat  patients  with  specific 
cancers. Extensive reviews of many inhibitors targeting 
these pathways have been recently published [2-4]. This 
figure  serves  as  a  starting 
for 
understanding  the  flow  of  information  through  the 
Ras/Raf/MEK/ERK pathway from a growth factor to a 
specific  receptor  to  phosphorylation  of  appropriate 
transcription factors in the nucleus, which modulate the 
expression  of  key  genes  [7-11].  The  effects  of  this 
pathway  on 
translational  apparatus  are  also 
diagrammed.  Often  mRNAs  encoding  growth  factors 
are  entitled  “weak”  mRNAs  and 
effects  of 
the  Ras/Raf/MEK/ERK  and  Ras/PI3K/ 
PTEN/Akt/mTOR  pathways  for  efficient  translation 
[2,4,11].  As  an  example,  we  present  the  autocrine 
production  of  a  growth  factor.  Importantly,  many 
components  and  interacting  members  of  this  pathway 
are  also  present  as  mutated  forms  in  the  genomes  of 
retroviruses 
in  experimental 
animals.  Thus  there  have  always  been  direct  pivotal 
links of this pathway with malignancy. 
 
After growth factor/cytokine/mitogen stimulation of the 
appropriate  (cognate)  receptor,  a  Src  homology  2 
domain  containing  protein  (Shc)  adaptor  protein 
becomes associated with the C-terminus of the specific 
(e.g.,  vascular 
activated  growth 
endothelial growth factor receptor [VEGFR], epidermal 
growth  factor  receptor  [EGFR],  insulin  like  growth 
factor-1  receptor [IGF-1R] and many others) [2-4]. Shc 
recruits the Grb2 protein and the son of sevenless (SOS) 
homolog protein, resulting in the loading of membrane-
bound Ras with GTP [7]. Ras can also be activated by 
growth factor receptor tyrosine kinases [GFRTK], such 
as  insulin  receptor  (IR),  via  intermediates  like  insulin 
receptor substrate (IRS) proteins that bind growth factor 
receptor-bound  protein  2  [7,8].  Ras:GTP  then  recruits 
Raf to the membrane where it becomes activated, likely 
via  a  Src-family  tyrosine  (Y)  kinase  [9].  At  this  point 

induced  cancer 

require 

factor 

receptor 

the          

the 

that 

  
www.impactaging.com 

 

 

 

          193                                          AGING, March 2011, Vol.3 No.3

we  will  be  somewhat  generic,  although  it  should  be 
pointed out that both Ras and Raf are members of multi-
gene families and there are three Ras members (Ki-Ras, 
N-Ras and Ha-Ras) [7] and three Raf members (B-Raf, 
Raf-1 [a.k.a c-Raf] and A-Raf) [9].  Raf is responsible for 
serine/threonine  (S/T)  phosphorylation  of  mitogen-
activated protein kinase kinase-1 (MEK1) [2,3,7]. MEK1 
phosphorylates ERK1 and 2 at specific T and Y residues 
[10].  Activated  ERK1  and  ERK2  serine  S/T  kinases 
phosphorylate  and  activate  a  variety  of  substrates, 
including  p90Rsk1 
[2,3,7,10].  ERK1/2  has  many 
downstream  and  even  upstream  substrates  (see  below). 
p90Rsk1 can activate the cAMP response element binding 
protein (CREB) transcription factor [13]. 
 
The number of ERK1/2 targets is easily in the hundreds 
(>600).  Thus  suppression  of  MEK  and  ERK  activities 
will  have  profound  effects  on  cell  growth  and  aging. 
Activated  ERK  can  also  phosphorylate  B-Raf,  Raf-1 
and  MEK1  which  alter  their  activity  (Figure  1). 
Depending upon the site phosphorylated on Raf-1, ERK 
phosphorylation can either enhance [14] or inhibit [15] 
Raf-1 activity. In contrast, when B-Raf [16] or MEK1 
[17]  are  phosphorylated  by  ERK, 
their  activity 
decreases.  These  phosphorylation  events  serve  to  alter 
the stability and/or activities of the proteins. This is the 
first  discussion  of  feed-back  loops  which  will  become 
important  in  consideration  of  whether  to  just  target 
MEK or to target both Raf and MEK in various cancers. 
It  is  important  that  the  reader  realize  that  certain 
phosphorylation events can either inhibit or repress the 
activity  of  the  affected  protein.  This  often  depends  on 
the  particular  residue  phosphorylated  on  the  protein 
which can confer a different configuration to the protein 
or 
to  a  different  subcellular 
localization that may result in proteasomal degradation. 
Furthermore, 
certain 
phosphorylation events will actually serve to shut off or 
slow  down  the  pathway.  Thus  protein  phosphorylation 
by  the  Ras/Raf/MEK/ERK  pathway  is  a  very  intricate 
process  which  serves  to  fine  tune  the  signal  often 
originating from a growth factor or mitogens. 
 
Activated  ERK  can  translocate  to  the  nucleus  and 
phosphorylate  additional  transcription  factors,  such  as 
Elk-1,  CREB,  Fos  and  globin  transcription  factor  1 
(Gata-1) and others [2-4, 14,18], that bind promoters of 
many genes, including growth factor and cytokine genes 
that are important in promoting growth and preventing 
apoptosis  of  multiple  cell 
types.  Under  certain 
circumstances,  aberrant  regulation  of  this  pathway  can 
contribute to abnormal cellular proliferation which may 
lead 
including;  autocrine 
transformation, 
or 
premature aging [2,4,5,19].  

to  many  abnormalities 

previously  mentioned, 

the  protein 

senescence 

resistance, 

target 

drug 

as 

in 

forming 

the 

and 

phospholipids 

of  membrane 

the 
thereby 

phosphatidylinositol 

The Ras/PI3K/PTEN/Akt/mTOR Pathway 
 
An  introductory  overview  of  the  Ras/PI3K/PTEN/ 
Akt/mTOR  pathway  is  presented  in  Figure  2.  Also 
outlined 
this  diagram  are  common  sites  of 
intervention  with  signal  transduction  inhibitors.  Many 
of  these  inhibitors  have  been  evaluated  in  various 
clinical trials and some are currently being used to treat 
patients  with  specific  cancers.  Extensive  reviews  of 
many  inhibitors  targeting  these  pathways  have  been 
recently  published  [2,4,19,20].  Phosphatidylinositol-3-
kinase (PI3K) is a heterodimeric protein with an 85-kDa 
regulatory  subunit  and  a  110-kDa  catalytic  subunit 
(PIK3CA)  [20,21].    PI3K  serves  to  phosphorylate  a 
series 
including 
phosphatidylinositol  4-phosphate 
(PtdIns(4)P)  and 
phosphatidylinositol  4,5-bisphosphate  (PtdIns(4,5)P2), 
catalyzing the transfer of ATP-derived phosphate to the 
D-3  position  of 
inositol  ring  of  membrane 
phosphoinositides, 
second 
messenger  lipids  phosphatidylinositol  3,4-bisphosphate 
(PtdIns(3,4)P2) 
3,4,5-
trisphosphate  (PtdIns(3,4,5)P3)  [4,19,20].  Most  often, 
PI3K  is  activated  via  the  binding  of  a  ligand  to  its 
cognate 
receptor,  whereby  p85  associates  with 
phosphorylated  tyrosine  residues  on  the  receptor  via  a 
Src-homology  2  (SH2)  domain.  After  association  with 
the  receptor,  the  p110  catalytic  subunit  then  transfers 
phosphate  groups  to  the  aforementioned  membrane 
phospholipids  [4,19,20].    It  is  these lipids,  specifically 
PtdIns(3,4,5)P3,  that  attract  a  series  of  kinases  to  the 
plasma  membrane 
the  signaling 
cascade [4,19,20].  
 
Downstream  of  PI3K  is  the  primary  effector  molecule 
of  the  PI3K  signaling  cascade,  Akt/  protein  kinase  B 
(PKB).  Akt  was  originally  discovered  as  the  cellular 
homologue of the transforming retrovirus AKT8 and as 
a kinase with properties similar to protein kinases A and 
C 
[4,19,21,22].  Akt  contains  an  amino-terminal 
pleckstrin homology (PH)  domain that serves to target 
the  protein  to  the  membrane  for  activation  [21,22]. 
Within its central region, Akt has a large kinase domain 
and is flanked on the carboxy-terminus by hydrophobic 
and  proline-rich  regions  [22].    Akt  is  activated  via 
phosphorylation of two residues: T308 and S473.   
 
The  phosphotidylinositide-dependent  kinases  (PDKs) 
are  responsible  for  activation  of  Akt.  PDK1  is  the 
kinase  responsible  for  phosphorylation  of  T308  [23]. 
Akt is also phosphorylated by the mammalian target of 
Rapamycin 
as 
(Rapamycin-insensitive  companion  of  mTOR/mLST8 
complex)  mTORC2  [4,19]  (See  Figures  2  &  3).     
Before  its  discovery,  the  activity  responsible  for  this  

initiating 

complex 

(mTOR) 

referred 

thereby 

to 

  
www.impactaging.com 

 

 

 

           194                                           AGING, March   2011, Vol.3 No.3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
Figure  1.  Overview  of  the  Ras/Raf/MEK/ERK  Pathway  and  Potential  Sites  of  Therapeutic  Intervention  with  Small 
Molecule Membrane‐Permeable Inhibitors. The Ras/Raf/MEK/ERK pathway is regulated by Ras (indicated in green ovals), 
as well as various upstream growth factor receptors (indicated in purple) and non‐receptor kinases. Sites where various small 
molecule inhibitors suppress this pathway are indicated by red octagons. The downstream transcription factors regulated by 
this pathway are indicated in purple diamond shaped outlines. The Ras/Raf/MEK/ERK pathway also interacts with key proteins 
involved in protein translation (indicated in green ovals). The Ras/Raf/MEK/ERK pathway aids in the assembly of the protein 
translation complex responsible for the translation of “weak” mRNAs (indicated in a red line folding over on itself) important 
in the prevention of apoptosis. This drawing depicts a relative common, yet frequently overlooked phenomenon in human 
cancer, autocrine transformation. GF = growth factor, GFR = growth factor receptor. 
 

  
www.impactaging.com 

 

 

 

          195                                           AGING, March    2011, Vol.3 No.3

 

 

 
  
www.impactaging.com 

Figure  2.  Overview  of  the  Ras/PI3K/PTEN/Akt/mTOR  Pathway  and  Potential  Sites  of  Therapeutic  Intervention.  The 
Ras/PI3K/PTEN/mTOR pathway is regulated by Ras (indicted in green ovals), as well as various upstream growth factor receptors 
(indicated  in  purple).  Sites  where  various  small  molecule  inhibitors  suppress  this  pathway  are  indicated  by  red  octagons. 
Naturally occurring miRNAs have been discovered to certain components of this pathway (e.g., PTEN) and are indicated in a red 
triangle;  other  miRNAs  to  other  components,  especially  tumor  suppressor  genes  will  likely  be  discovered.  The  downstream 
transcription  factors  regulated  by  this  pathway  are  indicated  in  diamond  shaped  purple  (active)  or  red  (inactivated)  outlines. 
This drawing depicts some of the complicated regulations of this pathway by both positive and negative phosphorylation events 
which serve to fine tune this pathway. Phosphorylation of some molecules by certain kinases (e.g., phosphorylation of β‐catenin 
by glycogen synthase kinase‐3β [GSK‐3β], indicated in red oval) results in their proteosomal degradation (indicated in red box), 
while  phosphorylation  of  some  molecules  by  certain  kinases  (e.g.,  β‐catenin  by  Akt)  results  in  their  activation  (nuclear 
translocation,  indicated  in  green  box).  The  Ras/PI3K/PTEN/Akt/mTOR  pathway  plays  a  key  role  in  regulating  p53  activity 
(indicated  in  purple  diamond)  by  phosphorylating  MDM2  (indicated  in  red  oval)  which  controls  the  stability  of  p53  by 
ubiquitination.  The  Ras/PI3K/PTEN/Akt/mTOR  pathway  plays  a  key  role  in  regulating  critical  proteins  involved  in  protein 
translation  (indicated  in  green  ovals),  especially  those  necessary  for  the  translation  of  “weak”  mRNAs  (mTORC1,  grouped 
together  a  purple  box).  This  pathway  also  indicates  that  Akt  can  result  in  the  activation  of  downstream  mTOR  which  can 
subsequently serve as either a negative feed back to inactivate Akt by p70S6K or activate Akt by mTORC2 (grouped together in a 
blue box). GF = growth factor, GFR = growth factor receptor. 

 

 

 

         196                                           AGING, March 2011, Vol.3 No.3

leaves 

survival 

and 

loops 

that 

serve 

to 

regulate 

proliferation, 

the  cell  membrane 

the  Ras/Raf/MEK/ERK  pathway, 

to  as  PDK2. 
phosphorylation  event  was  referred 
Therefore,  phosphorylation  of  Akt 
is  somewhat 
complicated  as  it  is  phosphorylated  by  a  complex  that 
lies downstream of activated Akt itself [4,19]. Thus, as 
there  are 
with 
feedback 
the 
Ras/PI3K/PTEN/Akt/mTOR  pathway.  Once  activated, 
Akt 
to  phosphorylate 
intracellular substrates. 
 
After activation, Akt is able to translocate to the nucleus 
[4,19,24]  where  it  affects  the  activity  of  a  number  of 
transcriptional regulators. CREB [25], E2F [26], nuclear 
factor kappa from B cells (NF-κB) via inhibitor kappa B 
protein  kinase  (Iκ-K)  [27],  the  forkhead  transcription 
factors  [28]  and  murine  double  minute  2  (MDM2) 
which regulates p53 activity. These are all either direct 
or  indirect  substrates  of  Akt  and  each  can  regulate 
epithelial 
cellular 
mesenchymal  transition  (EMT)  [4,11,19,28-31].  Aside 
from transcription factors, Akt is able to target a number 
of other molecules to affect the survival state of the cell 
including:  the  pro-apoptotic  molecule  Bcl-2-associated 
death  promoter  (BAD)  [29],  and  glycogen-synthase 
kinase-3β  (GSK-3β)  [30].  GSK-3β  regulates  -catenin 
protein  stability.  Hence  the  PI3K/PTEN/Akt/mTOR 
pathway  is  connected  to  the  Wnt/-catenin,  p53  and 
many additional pathways (Figure 3). 
 
Negative  regulation  of  the  PI3K  pathway  is  primarily 
accomplished through the action of the phosphatase and 
tensin  homologue deleted  on  chromosome  ten  (PTEN) 
tumor  suppressor  proteins.  PTEN  encodes  a  lipid  and 
protein  phosphatase  whose  primary  lipid  substrate  is 
protein 
PtdIns(3,4,5)P3 
substrate(s)  of  PTEN  are  more  varied,  including  focal 
adhesion  kinase  (FAK),  the  Shc  exchange  protein  and 
the  transcriptional  regulators  ETS-2  and  Sp1  and    the 
platelet-derived  growth  factor  receptor  (PDGFR)  [31-
33]. 
 
PTEN  has  four  primary  structural  domains.  On  the 
amino  terminus  is  the  lipid  and  protein  phosphatase 
domain, which is flanked adjacent to the C2 domain that 
is 
lipid  binding  and  membrane 
localization.  Next  are  two  protein  sequences  rich  in 
proline (P), glutamic acid (E), serine (S), and threonine 
(T)  (PEST)  domains  that  regulate  protein  stability.  
Lastly, PTEN has a PDZ domain, which helps facilitate 
protein-protein 
the 
phosphatase  domain  have  been  reported  to  nullify  the 
endogenous function of PTEN [31, 35]. Thus PTEN is 
an  enticing  therapeutic  target  for  activation  since  it  is 
frequently  inactivated  in  many  human  cancers  through 
point mutations as well as other means (e.g., promoter 

interactions.  Mutations  within 

[31-39].  The 

responsible 

for 

purported 

to 

from 

PtdIns(3,4,5)P3 

hypermethylation,  gene  deletion)  and  its  inactivation 
results  in  elevated  Akt  activity  and  abnormal  growth 
regulation [31, 35]. Moreover, PTEN can be inactivated 
by phosphorylation and oxidation in human cancer and 
which  results  in  elevated  Akt  activity  and  abnormal 
growth  regulation  [31,35,36].  Thus,  drugs  reactivating 
PTEN could potentially be very useful in some types of 
tumors driven by PTEN inactivation. 
 
Another negative regulator of the PI3K pathway is the 
PH  domain  leucine-rich  repeat  protein  phosphatase 
(PHLPP). PHLPP dephosphorylates S473 on Akt which 
induces apoptosis and inhibits tumor growth [37]. Two 
other  phosphatases,  SH2  domain-containing  inositol 
5’phosphatase  (SHIP)-1  and  SHIP-2,  remove  the  5-
produce 
phosphate 
PtdIns(3,4)P2 [38-41]. Mutations in these phosphatases, 
which  eliminate  their  activity,  can  lead  to  tumor 
progression.    Consequently,  the  genes  encoding  these 
phosphatases are referred to as anti-oncogenes or tumor 
suppressor genes.   
 
Next we discuss some of the key downstream targets of 
Akt that can also contribute to abnormal cellular growth 
and  are  key  therapeutic  targets  [4,19,35,42-47].  Akt-
mediated  regulation  of  mTOR  activity  is  a  complex 
multi-step phenomenon. Some of these targets and how 
they  interact  with  the  Ras/PI3K/PTEN/Akt/mTOR  and 
Ras/Raf/MEK/ERK pathways are indicated in Figure 3.  
Akt  inhibits  tuberous  sclerosis  2  (TSC2  or  hamartin) 
function  through  direct  phosphorylation  [4,19,35,42]. 
TSC2  is  a  GTPase-activating  protein  (GAP)  that 
functions  in  association  with  the  putative  tuberous 
sclerosis 1 (TSC1 or tuberin) to inactivate the small G 
protein Rheb [4,19,35,43,44]. TSC2 phosphorylation by 
Akt represses GAP activity of the TSC1/TSC2 complex, 
allowing  Rheb  to  accumulate  in  a  GTP-bound  state. 
Rheb-GTP then activates, through a mechanism not yet 
fully  elucidated,  the  protein  kinase  activity  of  mTOR 
when complexes with the Raptor (Regulatory associated 
protein  of  mTOR)  adaptor  protein,  DEPTOR  and 
mLST8,  a  member  of  the  Lethal-with-Sec-Thirteen 
gene  family,  first  identified  in  yeast  [4,19].  The 
mTOR/Raptor/mLST8 complex (mTORC1) is sensitive 
to  rapamycin  and,  importantly,  inhibits  Akt  via  a 
negative feedback loop which involves, at least in part, 
p70S6K  [44].  This  is  due  to  the  negative  effects  that 
p70S6K has on IRS1 [43] (see Figure 3). 
 
The  mechanism  by  which  Rheb-GTP  activates 
mTORC1 has not been fully elucidated yet, however it 
requires  Rheb  farnesylation  and  can  be  blocked  by 
farnesyl 
inhibitors.  It  has  been 
proposed  that  Rheb-GTP  would  relieve  the  inhibitory 
function of FKBP38 (another component of mTORC1) 

transferase  (FT) 

  
www.impactaging.com 

 

 

 

           197                                           AGING, March   2011, Vol.3 No.3

that, 

in  solid 

in  some  cell 

on  mTOR,  thus  leading  to  mTORC1  activation  [44]. 
However,  more  recent  investigations  did  not  confirm 
these findings [45]. 
 
Nevertheless, Akt also phosphorylates proline-rich Akt-
substrate-40  (PRAS40),  an  inhibitor  of  mTORC1,  and 
by  doing  so,  it  prevents  the  ability  of  PRAS40  to 
suppress  mTORC1  signalling  (recently  reviewed  in 
[4,19,44]).  Thus,  this  could  be  yet  another  mechanism 
by  which  Akt  activates  mTORC1.  Moreover,  PRAS40 
is  a  substrate  of  mTORC1  itself,  and  it  has  been 
demonstrated  that  mTORC1-mediated  phosphorylation 
of  PRAS40  facilitates  the  removal  of  its  inhibition  on 
downstream  signaling  of  mTORC1  [4,19,44].  Also 
Ras/Raf/MEK/ERK  signaling  positively  impinges  on 
Indeed,  both  p90Rsk-1  and  ERK  1/2 
mTORC1. 
phosphorylate  TSC2,  thus  suppressing  its  inhibitory 
function  [4,19,44]  (See  Figure  3).  Moreover,  recent 
evidence  has  highlighted 
tumors, 
mTORC1  inhibition  resulted  in  ERK  1/2  activation, 
through p70S6K/PI3K/Ras/Raf/MEK [46]. 
 
The  relationship  between  Akt  and  mTOR  is  further 
complicated  by  the  existence  of  the  mTOR/Rictor 
complex  (mTORC2),  which, 
types, 
displays  rapamycin-insensitive  activity.  mTORC2  has 
been  found  to  directly  phosphorylate  Akt  on  S473  in 
vitro  and  to  facilitate  T308  phosphorylation.  Thus, 
mTORC2  can  function  as  the  elusive  PDK-2  which 
phosphorylates  Akt  on  S473  in  response  to  growth 
factor  stimulation  [47].  Akt  and  mTOR  are  linked  to 
each other via positive and negative regulatory circuits, 
which 
their  simultaneous  hyperactivation 
through  a  mechanism  involving  p70S6K  and  PI3K 
[4,19,35,44,48-55].  Assuming  that  equilibrium  exists 
between  these  two  complexes,  when  the  mTORC1 
complex is formed, it could antagonize the formation of 
the mTORC2 complex and reduce Akt activity [44-46]. 
Thus,  at  least  in  principle,  inhibition  of  the  mTORC1 
complex could result in Akt hyperactivation. This is one 
problem  associated  with  therapeutic  approaches  using 
rapamycin that block some actions of mTOR but not all. 
 
mTOR is a 289-kDa S/T kinase. It regulates translation 
in  response 
to  nutrients  and  growth  factors  by 
phosphorylating  components  of  the  protein  synthesis 
machinery,  including  p70S6K  and  eukaryotic  initiation 
factor  (eIF)-4E  binding  protein-1  (4EBP-1),  the  latter 
resulting in release of the eukaryotic initiation factor-4E 
eIF-4E, allowing eIF-4E to participate in the assembly 
of  a 
initiation  complex  [4,19,35,44]. 
p70S6K  phosphorylates  the  40S  ribosomal  protein  S6, 
(rpS6), 
translation  of  mRNAs 
[4,19,35,44].  Integration  of  a  variety  of  signals 
(mitogens, growth factors, hormones) by mTOR assures 

translational 

to  active 

restrain 

to 

the 

leads 

the  mRNAs  encoding 

cell  cycle  entry  only  if  nutrients  and  energy  are 
sufficient  for  cell  duplication  [4,  48-52].  Therefore, 
mTOR  controls  multiple  steps  involved  in  protein 
synthesis,  but  importantly  enhances  production  of  key 
molecules  such  as  c-Myc,  cyclin  D1,  p27Kip1,  and 
retinoblastoma protein (pRb) [35].  
 
translation  of  hypoxia-
mTOR  also  controls 
transcription  factor-1  (HIF-1)  mRNA 
inducible 
[51,52].  HIF-1  upregulation 
increased 
expression  of  angiogenic  factors  such  as  vascular 
endothelial  growth  factor  (VEGF)  and  PDGF  [4]. 
Moreover, HIF-1 regulates the glycolytic pathway by 
controlling the expression of glucose-sensing molecules 
including  glucose  transporter  (Glut)  1  and  Glut3  [51]. 
By  regulating  protein  synthesis,  p70S6K  and  4E-BP1 
also  control  cell  growth  and  hypertrophy,  which  are 
important  processes  for  neoplastic  progression.  Hence 
targeting  the mTOR  pathway  could  have  many  effects 
on the regulation of cellular growth.  
 
Many  of 
the  previously 
mentioned  genes  contain  5’untranslated  regions  which 
are G+C rich and difficult to translate and referred to as 
weak mRNAs [35]. 4EP-B1 forms a complex with these 
the 
mRNAs  and  other  binding  factors  allowing 
translation  of 
[35,53-58]. 
Rapamycin  and  mTOR  kinase  inhibitors  suppress  the 
translation  of  these  critical  mRNAs  involved  in  cell 
survival and growth.   
 
Control  of  Apoptotic  Regulatory  Molecules  by          
the  Ras/Raf/MEK/ERK  and  Ras/PI3K/Akt/mTOR 
Pathways 
 
These  two  pathways  regulate  the  activity  of  many 
proteins involved in apoptosis. In the following section, 
we  will  mainly  discuss  the  effects  of  these  pathways 
elicited  by post-translational mechanisms [2, 3, 58-62], 
although it should be noted that both ERK and Akt also 
phosphorylate  transcription  factors  that  influence  the 
transcription  of  the  Bcl-2  family  of  genes  as  well  as 
other  important  genes  involved  in  the  regulation  of 
apoptosis [2, 4, 35, 60-62]. Many of the effects of the 
Ras/Raf/MEK/ERK 
Ras/PI3K/Akt/mTOR 
pathways  on  apoptosis  are  mediated  by  ERK  or  Akt 
phosphorylation  of  key  apoptotic  effecter  molecules 
(e.g., Bcl-2, Mcl-1, Bad, Bim, CREB, Foxo, Caspase-9 
and  many  others)  [2,  4,  35,  59-62].  In  addition,  both 
pathways  regulate  the  translation  of  weak  mRNAs. 
ERK,  p90Rsk-1,  MNK1/2  and  p70S6K  regulate  the 
phosphorylation of many of the proteins involved in the 
key  complex  required  for  the  translation  of  the  weak 
mRNAs  [35,44,56,57].  In  some  cases,  members  of  the 
two pathways (e.g., p90Rsk-1 and p70S6K) will phosphor- 

these  weak  mRNAs 

and 

leading 

  
www.impactaging.com 

 

 

 

          198                                           AGING, March   2011, Vol.3 No.3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
Figure 3. Interactions between the Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/mTOR and Wnt/‐Catenin Pathways that Result 
in  the  Regulation  of  Protein  Translation  and  Gene  Transcription.  The  Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways can affect protein translation by complex interactions regulating the mTORC1 (grouped together in a purple box) and 
mTORC2  (grouped  together  in  a  blue  box)  complexes.  GF  stimulation  results  in  GFR  activation  which  can  activate  both  the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways. Akt can phosphorylate and inhibit the effects of GSK‐3β, TSC2 and 
PRAS‐40 (indicated in red ovals), which result in mTORC1 activation. ERK and PDK1 can phosphorylate p90Rsk1 (indicated in green 
ovals), which in turn can phosphorylate and inhibit TSC2 (indicated in red oval). Akt‐mediated phosphorylation of GSK‐3 also 
affects the Wnt/‐catenin pathway and EMT. Rapamycin targets mTORC1 and inhibits its activity and also results in inhibition of 
downstream p70S6K. The effects of rapamycin are complex as long term administration of rapamycin may prevent mTOR from 
associating with mTORC2 and hence full activation of Akt is prevented. However, rapamycin treatment may result in activation 
of PI3K, by inhibiting the effects of p70S6K on IRS‐1 phosphorylation which results in PI3K and Akt activation. Also rapamycin 
treatment may result in the activation of ERK in some cells, presumably by inhibition of the p70S6K mediated inhibition of IRS1. 
These later two effects of rapamycin could have positive effects on cell growth. Energy deprivation will result in the activation of 
serine/threonine  kinase  11  (STK11  a.k.a  LKB1)  and  AMP  kinase  (AMPK)  which  can  result  in  TSC2  activation  (indicated  in  red 
ovals) and subsequent suppression of mTORC1. In contrast Akt can phosphorylate and inhibit the activity of AMPK. Inhibition of 
PDK‐1  activity  can  also  result  in  activation  of  mTORC1,  presumably  by  suppression  of  p70S6K  and  hence  inhibition  of  IRS1 
(indicated  in  red  oval)  effects  on  PI3K  activity.  The  PTEN,  TSC1,  TSC2  and  LKB1  tumor  suppressor  genes  all  converge  on  the 
mTORC1 complex to regulate protein translation. Thus the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can finely 
tune protein translation and cell growth by regulating mTORC1. Rapamycin can have diverse effects on these processes. Also 
these pathways can interact with the Wnt/‐catenin pathway which is important  in developmental processes, EMT and CICs. 
Upon activation of the Wnt pathway, ‐catenin forms a complex with Bcl‐9, PYGO, plakoglobulin and TCF/LEF which result in the 
transcription of critical genes including cyclin D1, c‐Myc, SALL4 and PPAR. 
 

  
www.impactaging.com 

 

 

 

          199                                           AGING,   March 2011, Vol.3 No.3

auto-immune 

ylate  the  same  molecule  in  the  translation  complex  at 
the same site e.g. ribosomal protein S6 (rpS6) [57, 58]. 
However, the kinetics of phosphorylation of rpS6 by the 
two  kinases  differs.  Thus  these  two  pathways  regulate 
the  activity  of  this  translation  complex  which  is 
responsible for the translation of certain weak mRNAs 
involved  in  regulation  of  apoptosis.  Mcl-1  is  an 
example of a weak mRNA and it plays key roles in the 
regulation of apoptosis. 
 
Aberrant regulation of apoptosis is critically implicated 
in  cancer  as  well  as  many  other  diseases  (e.g., 
inflammation, 
diseases).  Therefore 
controlling  the  activity  of  the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  pathways  have  been  keen 
pharmaceutical objectives for many years. The activity 
of  many  key  components  in  apoptotic  cascades  is 
sensitive to inhibitors that target these pathways.  
 
Akt  regulates  the  apoptotic  response  to  a  variety  of 
stimuli via its ability to interact with a number of key 
players  in  the  apoptotic  process  [2,4,61,62].    Akt  can 
directly  phosphorylate  BAD  on  S136,  causing  its 
inactivation  preventing  it  from  interacting  with  anti-
apoptotic members of the Bcl-2 family of proteins (Bcl-
2,  Bcl-XL)  [29,62].    Activated  Akt  can  inhibit  the 
release  of cytochrome  c  from  the  mitochondria,  which 
is  a  potent  activator  of  the  apoptotic  caspase  cascade 
[59].  The Akt target, Foxo-3 is capable of upregulating 
Fas  ligand  (Fas-L)  and  Bim,  two  very  important 
molecules 
inducers  of  apoptosis; 
however, when inactivated by Akt, Foxo-3 is localized 
to the cytosol where it is unable to augment expression 
of these genes [28,60]. Akt can also phosphorylate Bim 
which inhibits its proapoptotic activity [61]. In concert, 
these events caused by Akt activation affect the survival 
status of the cell.  
 
Frequent Oncogenic Mutations at Members of these 
Pathways  Result 
for 
Therapeutic Targeting of these Pathways 
 
Effective  targeting  of  signal  transduction  pathways 
activated  by  mutations  and  gene  amplification  may  be 
an  appropriate  approach 
limit  cancer  growth, 
metastasis,  drug  resistance  as  well  as  aging.  The 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways 
amplifications of upstream growth factor receptors. The 
abnormal  production  of  growth  factors  can  result  in 
receptor  activation  which 
the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
cascades.  An  illustration  of  some  of  the  receptors, 
exchange  factors,  kinases  and  phosphatases  that  are 
mutated/amplified in human cancer and how they may 

in  Activation:  Rationale 

that  are  potent 

turns  mobilizes 

activated 

can 

be 

to 

by  mutations/    

in 

the 

(rarely) 
factor 

[81-84], 
(ETS) 

Ras/Raf/MEK/ERK 

impact 
and 
Ras/PI3K/PTEN/Akt/mTOR  cascades  is  presented  in 
Figure 4.   
 
Perhaps one of the biggest advances in medical science in 
the  1980’s  was  the  confirmation  of  the  proto-oncogene 
hypothesis, that predicted that the human genome contains 
genes  related  to  viral  oncogenes  which  when  mutated 
could  cause  human  cancer  [4,7,19,35,62-84].  Key    
genetic  members  of  the  Ras/Raf/MEK/ERK  pathway           
[e.g.,  RAS,  RAF),  MEK 
the 
the 
downstream 
transcription 
(e.g.,  PIK3CA,  AKT, 
Ras/PI3K/PTEN/Akt/mTOR 
PTEN)  pathway  and  upstream  receptors  (e.g.,  ERBB1 
(EGF-R),  ERBB2  (HER2),  PDGFR,  KIT,  FLT3,  FMS) 
were  shown  to  fulfill  this  hypothesis  as  they  were 
sometimes mutated/amplified/deleted in specific human 
cancers.  The  RAS,  RAF,  PIK3CA,  AKT,  ERBB1,  KIT, 
FMS  and  ETS  oncogenes  are  also  contained  as  viral 
oncogenes  in  the  genomes  of  certain  retroviruses  that 
cause  cancer  in  animals  [2,7,35,62].  Furthermore, 
genetic mutations at these cellular oncogenes often alter 
sensitivity  to  specific  targeted  therapeutic  approaches.  
Thus many of the genes in these two signal transduction 
pathway  can  cause  cancer  under 
the  appropriate 
conditions.  
 
Mutation  of  Upstream  Receptors  that  Activate  the 
Ras/Raf/MEK/ERK 
and  Ras/PI3K/Akt/mTOR 
Pathways in Human Cancer 
 
Amplification/overexpression of HER2 [human epidermal 
growth  factor  receptor, a.k.a.,  c-ErbB-2,  (ERBB2)]  is  an 
important  cause  of  sporadic  breast  cancer  that  occurs  in 
approximately 30% of breast cancer. HER2 is a receptor 
tyrosine  kinase  (RTK)  [85].  HER2  can  heterodimerize 
with  c-ErbB-3  which  has  six  docking  sites  for  PI3K. 
While  a  normal  breast  cell  possesses  20,000  to  50,000 
HER2  molecules,  amplification  of  this  gene  in  HER2+ 
cancers  can  increase  levels  of  HER2  up  to  2,000,000 
molecules  per  cell  [85].  Overexpression  of  HER2  is 
linked  to  comedo  forms  of  ductal  carcinoma  in  situ 
(DCIS) and occurs in approximately 90% of these cases. 
HER2 
expression  of  both  the  Ras/PI3K/Akt/PTEN/mTOR  and 
Ras/Raf/MEK/ERK  pathways.  Association  of  genes  that 
regulate signal transduction pathways with breast cancer 
implies an important role of these pathways in neoplasia. 
 
In  acute  myeloid  leukemia  (AML),  activation  of  the 
Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathway 
can result from mutated upstream targets such as class 
III RTKs. These include point mutations such as FLT3-
internal  tandem  duplications  (FLT3-ITD)  and  mutated 
c-KIT,  which  are  present   in   35-40%   of  all  AML  

overexpression  will 

increased        

lead 

to 

  
www.impactaging.com 

 

 

 

          200                                           AGING, March   2011, Vol.3 No.3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[2,4,35,62].  Mutations  in  upstream  signaling  molecules 
such  as  KIT  and  FLT3  are  believed  to  activate  the 
downstream  signal 
transduction  cascades,  such  as 
Ras/Raf/MEK/ERK  and Ras/PI3K/Akt/mTOR pathways.  
 

 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutations at RAS in Human Cancer 
 
Mutations  that  lead  to  expression  of  constitutively-
active Ras proteins have been observed in approximate- 
 

 

Figure 4. Dysregulated Expression of Upstream Receptors and Kinases Can Result in Activation of the Ras/Raf/MEK/ERK 
and Ras/PI3K/PTEN/Akt/mTOR Pathways.  Sometimes  dysregulated  expression  of  growth  factor  receptors  occurs  by  either 
increased expression or genomic amplifications (e.g., VEGFR, EGFR, HER2, IGF1R). Mutations have been detected in EGFR, FLT3, 
KIT, PDGFR, PIK3CA, RAS, BRAF, MEK1/MEK2, SOS,  PTPN11 (indicated in red ovals), and PTEN (indicated in a purple square) . Akt 
and Rheb are overexpressed in certain cancers. Other signaling molecules which may be overexpressed (e.g., IGF‐1R, VEGF‐R, 
ERK,  mTOR,  p70S6K)  but  not  necessarily  mutated  or  amplified  are  indicated  in  yellow  ovals.  The  MDM2  ubiquitin  ligase  is 
indicated in a green oval. The p53 tumor suppressor is one of the most frequently inactivated genes in human cancer and has 
multiple effects on these pathways and is indicated in a purple oval. Amplifications of HER2 and EGFR are detected in certain 
cancer  types.  The  BCRABL  chromosomal  translocation  is  present  in  virtually  all  chronic  myeloid  leukemias  (CMLs)  and  some 
acute  lymphatic  leukemias  (ALLs).  Many  of  these  mutations  and  chromosomal  translocations  result  in  the  activation  of  the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR  cascades.  These  pathways  can  also  be  activated  by  autocrine  growth 
stimulation, the genetic basis of which is frequently unknown. Deregulated expression of these pathways can result in cancer as 
well as premature aging. 

  
www.impactaging.com 

 

 

 

           201                                         AGING, March 2011, Vol.3 No.3

In 

the 

and 

also 

Raf/MEK/ERK 

cholangiocarcinoma,  KRAS 

ly  20  to  30%  of  human  cancers  [7,63-69].  The 
frequency of RAS mutations and other key genes in the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways  in  various  types  of  cancers  is  presented  in 
Table  1.  Often  point  mutations  are  detected  in  RAS 
genes in cancer cells from patients which enhance Ras 
activity.  Genome  RAS  amplification  or  overexpression 
of  Ras,  perhaps  due  to  altered  methylation  of  its 
promoter  region,  are  also  detected  in  some  tumors 
[7,63-69]. 
gene 
mutations  have  been  identified  in  45%  of  examined 
tumors [7]. Ras mutations are present in up to 20% of 
AML [67] and are another major cause of activation of 
this cascade. The frequency of KRAS mutations is very 
high  (~80%)  in  advanced  pancreatic  cancers  [7,63]. 
Mutations  that  result  in  increased  Ras  activity  often 
perturb 
the 
PI3K/PTEN/Akt/mTOR cascades [7].  
 
A  key  event  in  the  activation  of  the  Ras  protein  is 
farnesylation. Inhibitors that target the enzyme farnesyl 
transferase (FT) have been developed with the goal of 
targeting  Ras  [2].  Clinical  testing  of  FT  inhibitors 
(FTIs)  unfortunately  has  yielded  disappointing  results. 
The lack of usefulness of FTIs may be due to multiple 
reasons. First, there are many proteins that are regulated 
by FT. Second, although H-Ras is exclusively modified 
by FT and K-Ras to a lesser extent, N-Ras can also be 
modified 
This  modified  N-Ras  is  still  able  to  support  the 
biological  requirement  of  Ras  in  the  cancer  cell. 
Geranylgeranylation  of  K-Ras  and  N-Ras  become 
critical  only  when  farnesylation  is  inhibited.  The 
majority  of  RAS  mutations  in  humans  occur  in  KRAS, 
which is followed by NRAS [7,67]. The mutation rate at 
HRAS  is  a  distant  third  [7].  Hence,  it  is  very  possible 
that  the  effects  that  FTIs  had  in  initial  clinical  trials 
were not due to inhibition of mutant RAS genes present 
in the cell, but in fact resulted from non-specific effects 
which are related to the first point mentioned. Another 
important  target  of  FTIs  is  the  Rheb  protein  (Ras 
homologue  enriched  in  brain)  (See  Figure  2).  Rheb, 
another GTP binding/exchange protein, plays key roles 
in regulating mTORC1 and controlling the efficiency of 
protein translation [4,19,35].  
 
Mutations at RAF in Human Cancer 
 
Prior to 2003, it was believed that the RAF oncogenes 
were not frequently mutated in human cancer. There are 
three RAF genes in humans, (ARAF, BRAF and CRAF 
(a.k.a.  Raf-1)  encoding  three  distinct  proteins  with 
diverse  and  common  functions.  With  the  advent  of 
improved  methods  of  DNA  sequencing, 
it  was 
demonstrated  that  BRAF  is  frequently  mutated  in 

geranylgeranyltransferase 

by 

melanoma (27 to 70%), papillary thyroid cancer (36 to 
53%), colorectal cancer (5 to 22%), cholangiocarcinoma 
(22%),  ovarian  cancer  (30%),  and  a  small  minority  of 
lung  cancer  patients  (1-3%)  [70-75].  BRAF  mutation 
occurs  in  approximately  7%  of  all  cancers  [70-73].  In 
contrast,  CRAF  and  ARAF  are  not  believed  to  be 
frequently mutated in human cancer [80-81].  
 
It was proposed that the structures of B-Raf, Raf-1 and 
A-Raf  kinases  may  dictate  the  ability  of  activating 
mutations  to  occur  at,  and  be  selected  in,  the  genes 
encoding these proteins, which can permit the selection 
of oncogenic forms [75]. These predictions have arisen 
from  the  solved  structure  of  B-Raf  [75].  Like  many 
enzymes,  B-Raf  is  proposed  to  have  small  and  large 
lobes,  which  are  separated  by  a  catalytic  cleft.  The 
structural  and  catalytic  domains  of  B-Raf  and  the 
importance of the size and positioning of the small lobe 
may be critical in its ability to be stabilized by certain 
activating  mutations.  In  contrast, 
the  functionally 
similar mutations in ARAF and CRAF are not predicted 
to result in small lobe stabilization, this may prevent or 
hinder  the  selection  of  mutations  at  ARAF  and  CRAF, 
which would result in activated oncogenes [75]. 
 
The most frequent mutation detected at the BRAF gene 
is a change at amino acid 600, which converts a Val to 
Glu (Val600→Glu, V600E) [72]. This BRAF mutation 
accounts  for  >  90%  of  the  BRAF  mutations  found  in 
melanoma  and  thyroid  cancer.  BRAF  mutations  may 
arise in certain cells that express high levels of B-Raf as 
a  result  of  hormonal  stimulation.  Certain  hormonal 
signaling events will elevate intracellular cAMP levels, 
which 
to 
proliferation. Melanocytes and thyrocytes are two such 
cell types that have elevated B-Raf expression, as they 
are often stimulated by the appropriate hormones [76]. 
Moreover, it is thought that B-Raf is the most important 
kinase in the Ras/Raf/MEK/ERK cascade [75]. In some 
models,  wild-type 
(WT)  and  mutant  B-Raf  are   
proposed  to activate  Raf-1,  which then activates  MEK 
and  ERK  [77,78].  A  number  of  pharmaceutical  and 
biotechnological  companies  have  developed  inhibitors 
that  specifically  target  mutant  B-Raf  alleles  (mutant-
allele  specific  inhibitors), which  do  not  inhibit  WT B-
Raf [3]. 
 
In  many  cancers  with  BRAF  mutations,  the  mutations 
are  believed  to  be  initiating  events  and  also  the      
driver  mutations,  but  are  not  sufficient  for  complete 
neoplastic  transformation  [35,65,66,72-75].  Mutations 
at  other  genes 
the 
Ras/PI3K/PTEN/Akt/mTOR  pathway)  have  been 
hypothesized 
to  be  also  necessary  for  malignant 
transformation in some  cancers.  Moreover,  there  may 

in  B-Raf  activation, 

in  components  of 

leading 

result 

(e.g., 

(GGT).         

  
www.impactaging.com 

 

 

 

          202                                          AGING, March 2011, Vol.3 No.3

Mutations of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Pathways in Human Cancer 
Reference 

Gene 
RAS genes can be activated by point mutations, gene amplifications and other mechanisms. 
RAS 
7 

Approximate Reported Frequency 

Cancer Mutated At 

20-25% all human cancers, 
KRAS mutations account for 
about 85%, NRAS for about 

15%, HRAS for <1%. 

Many different types 
including pancreatic, acute 
myeloid leukemia, 
endometrial, lung, 
colorectal  
Pancreatic 
Thyroid (papillary) 

KRAS 
HRAS, KRAS, 
NRAS 
HRAS, KRAS, 
NRAS 
KRAS 
KRAS, NRAS 
NRAS, KRAS  Myelodysplastic syndrome 
KRAS 

Colorectal 
Seminoma 

Thyroid (follicular) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

NRAS 

NRAS 
KRAS 
NRAS 
HRAS 
HRAS 
 

BRAF 
BRAF 
BRAF 
BRAF 
 

PIK3CA 

PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 

 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non Small Cell Lung 
Carcinoma 
Acute myelogenous 
leukemia 
Liver 
Endometrial 
Melanoma 
Bladder 
Kidney 
 

Melanoma 
Papillary Thyroid  
Serous Ovarian 
Colorectal 
 

One of the most frequently 
mutated kinases in human 
cancer 
Breast 
Endometrial 
Hepatocellular 
Colon 
Prostate 
Glioblastoma 
Head/Neck Squamous Cell 

90% 
60% 

55% 

45% 
45% 
40% 
35% 

30% 

7 
7 

7 

7 
7 
7 
7 

7 

30% 
20% 
15% 
10% 
10% 

 

 

27-70% 
36-53% 

30% 
5-22% 

7 
7 
7 
7 
7 
 

72 
72 
72 
72 
 

BRAF is activated in approximately 7% all cancers, highest in melanoma, often activated by point 

PIK3CA is often activated by point mutations, also by gene amplification. 

>30% solid cancers 

106, 110 

8-40% 
23-36% 

36% 

19-32% 

29% 
5-27% 
33% 

106, 108, 110 

106, 110 

106, 108, 110 

110 
31 

106, 110 
106, 110 

  
www.impactaging.com 

 

 

 

          203                                          AGING, March 2011, Vol.3 No.3

PIK3CA 
PIK3CA 
PIK3CA 

PIK3CA 
PIK3CA 

PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
PIK3CA 
 

Gastric 
Urinary Track 
Anaplastic 
Oligodendroglioma 
Ovarian 
Intraductal Papillary 
Mucinous Neoplasm 
Carcinoma of the pancreas 
Upper Digestive Track 
Stomach 
Esophagus 
Oral Squamous Cell 
Pancreas 
Medulloblastoma 
Lung 
Hematopoietic & Lymphoid 
Skin 
Anaplastic Astrocytoma 
Thyroid 
 

25% 
17% 
14% 

6-12% 
11% 

106, 110 

31 

106, 110 

110 
110 

31 
31 
31 
110 
31 
110 
110 
31 
31 
110 
31 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cancers. 
 
 
 
 
 
 
 
 

10% 
8% 
7% 
7% 
6% 
5% 
4% 
4% 
3% 
3% 
2% 

 

 

PTEN often inactivated by deletion, gene methylation, protein stability and other genetic mechanisms. 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
PTEN 
 

Endometrial  
Central nervous system  
Skin 
Prostate 
Colon 
Urinary track 
Lung 
Ovary 
Breast 
Hematopoietic & Lymphoid 
Thyroid 
Stomach 
Liver 
Upper aerodigestive track 
Esophagus 
Pancreas 
 

38% 
20% 
17% 
14% 
9% 
9% 
8% 
8% 
6% 
6% 
5% 
5% 
5% 
4% 
1% 
1% 

31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
31 
 

AKT is infrequently mutated in human cancer but AKT2 gene can undergo amplification in certain 

AKT1 

AKT1 

AKT1 

 

Thryoid 

Breast 

Endometrial 

5% 

3% 

3% 

www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 

  
www.impactaging.com 

 

 

 

          204                                          AGING, March 2011, Vol.3 No.3

TSC1/TSC2 is inactivated by point mutations, deletion and other genetic mechanisms. Only TSC1is 

associated with some human cancers. 

AKT1 

Ovary 

AKT2 

AKT1 

AKT1 

AKT1 

AKT1 

Prostate 

TSC1 
 

Urinary track 

Large Intestine 

Urothelial Carcinoma 

AKT2 
AKT2 
AKT2 
 

Hematopoietic & Lymphoid 
tissue 
Head and Neck squamous 
cell carcinomas 
Pancreatic 
Ovarian 
Breast 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
be  certain  situations  where  certain  potent  BRAF 
mutations  (Val600→Glu)  and  RAS  mutations  are  not 
permitted  in  the  same  cell,  as  they  might  result  in 
hyperactivation  of  Ras/Raf/MEK/ERK  signaling  and 
expression, which could lead to cell cycle arrest [75]. In 
contrast,  there  are  other  cases  that  require  both  BRAF 
and  RAS  mutations  for  transformation.  The  BRAF 
mutations in these cases may result in weaker levels of 
B-Raf  activity  which  is  insufficient  for  abnormal 
proliferation [65,66,75,77,78]. It should be pointed out 
that RAS mutations may also result in activation of the 
Ras/PI3K/Akt/mTOR pathway. 
 
Different BRAF mutations have been mapped to various 
regions  of  the  B-Raf  protein.  Mutations  at  BRAF  that 
result  in  low kinase  activity  may  signal  through  Raf-1 
[75,77,78]. Heterodimerization between B-Raf and Raf-
1  proteins  may  allow  the  impaired  B-Raf  to  activate 
Raf-1.  Other  mutations,  such  as  Asp593→Val,  may 
activate alternative signal transduction pathways [75]. 
 
One  study  has  observed  that  mutated  alleles  of  CRAF 
are  present  in  therapy-induced  acute  myelogenous 
t-AML  arose  after 
leukemia  (t-AML)  [80].  This 
chemotherapeutic  drug 
treatment  of  breast  cancer 
patients. The mutated CRAF genes were transmitted in 
the  germ 
they  were  not  spontaneous 
mutations in the leukemia, but they may  be associated 
with  the  susceptibility  to  induction  of  t-AML  in  the 

thus, 

line, 

 

31 

1% 

1% 

1% 

1% 

1% 

159 

15% 

31 
31 
31 
 

www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 

 
 
 
 
 
 
 
 
 
 
 
30% amplified 
 
 
 
20% amplified 
 
12% amplified 
 
3% amplified 
 
 
 
 
 
 
 
 
 
 
breast  cancer  patients  studied.  Subsequent  studies 
demonstrated  that  blast  cells  from  patients  with  the 
CRAF  germline  mutations  also  had  loss  of  the  tumor 
and  metastasis  suppressor  Raf  kinase  inhibitor  protein 
(RKIP) [81]. The importance of RKIP was determined 
by transfection experiments with either siRNA directed 
against  RKIP  or  expression  vectors  overexpressing 
RKIP  [81].  The  levels  of  RKIP  were  determined  to 
influence  the  levels  of  CRAF-mediated  transformation 
as  high  levels  of  RKIP  suppressed  CRAF-mediated 
transformation,  while  low  levels  enhanced  CRAF-
mediated 
[81].  Decreased  RKIP 
expression  has  also  been  observed  in  some  cutaneous 
squamous  cell  carcinomas  which  also  displayed 
decreased BRAF expression [79]. Thus mutation at both 
BRAF and CRAF have been detected in certain cancer 
patients and other studies have shown that the levels of 
mutant and WT B-Raf, Raf-1 and RKIP will influence 
the levels of  transformation  observed,  hence there  is a 
strong basis for the development of Raf inhibitors [3]. 
 
Mutations  downstream  of  Raf 
the  Ras/Raf/ 
MEK/ERK  cascade  have  not  been  frequently  detected 
in human cancer although there are some rare germline 
mutations  detected 
in 
cardiofaciocutaneous  syndrome  (CFC)  [82].    There    
the 
are  also  mutations  at  other  components  of 
including  KRAS  and 
Ras/Raf/MEK/ERK  pathway 
BRAF  in  CFC.  There  are  mutations  at  components  of 

transformation 

and  MEK2 

at  MEK1 

in 

  
www.impactaging.com 

 

 

 

          205                                          AGING, March 2011, Vol.3 No.3

poor.  Therefore, 

the Ras/Raf/MEK/ERK pathway in the related Costello 
and  Noonan  syndromes,  including:  SOS,  and  PTPN11 
(Shp2)  in  Noonan  syndrome  and  HRAS  mutations  in 
Costello  syndrome  [83].  These  germline  mutations 
confer  sensitivity  to  MEK  inhibitors.  MEK1  but  not 
ERK2  mutations  have  been  observed 
in  some 
melanomas and colon carcinomas [84].   
 
Activation of the Ras/Raf/MEK/ERK Cascade in the 
Absence of Mutations in the Pathway 
 
Hepatocellular  carcinoma  (HCC)  is  the  fifth  most 
common cancer worldwide and the third most prevalent 
cause of cancer mortality, accounting for approximately 
6%  of  all  human  cancers  and  more  than  600,000    
deaths  annually  worldwide  [85,86].  Although 
the 
clinical diagnosis and management of early-stage HCC 
has  improved  significantly,  HCC  prognosis  is  still 
extremely 
investigating  HCC 
pathogenesis and finding new diagnostic and treatment 
strategies is important. 
 
Signaling  via  the  Ras/Raf/MEK/ERK  cascade  plays  a 
critical  role  in  liver  carcinogenesis  [86-91].  Although 
mutations of Ras and Raf occur infrequently in HCC, a 
that  activation  of  Ras 
recent  study  demonstrated 
pathway occurred in 100% of HCC specimens analyzed 
when compared with non-neoplastic surrounding tissues 
and normal livers [91].  
 
In  addition,  activation  of  Ras/Raf/MEK/ERK  pathway 
in  HCC  may  be  due  to  down-regulation  of  Ras 
inhibitors Sprouty and the Sprouty-related protein with 
Ena/vasodilator-stimulated phosphoprotein homology-1 
domain  (Spred-1)  and  Spred-2  proteins  [92,93].  It  has 
been  shown  that  the  expression  of  Spred-1  and  -2  in 
human  HCC 
in 
comparison  to  adjacent  non-tumorous  tissues.  This 
decreased  expression  inversely  correlated  with  the 
incidences  of  tumor  invasion  and  metastasis  [92]. 
Moreover, ectopic Spred expression inhibited HCC cell 
proliferation  both  in  vitro  and  in  vivo,  which  was 
associated with reduced ERK activation, suggesting that 
Spred could be both a novel prognostic factor and a new 
therapeutic target for human HCC [93].  
 
Down-regulation of RKIP expression is a  major factor 
in  activation  of 
the  Ras/Raf/MEK/ERK  pathway   
during  human  hepatocarcinogenesis 
[94].  These   
studies  indicate  the  complex  interplay  of  various    
genes  that  serve  to  regulate  the  Ras/Raf/MEK/ERK 
pathway.  Deregulation  of  their  expression  by  various 
(e.g.,  promoter  methylation,  point 
mechanisms 
mutations, post-translational mechanisms) may result in 

is  frequently  decreased, 

tissues 

for 

in  heptocarcinogenesis.  HBx 

Ras/Raf/MEK/ERK  pathway  activation  in  the  absence 
of detectable mutations at either RAF or MEK. Hence, 
the  Ras/Raf/MEK/ERK  cascade  is  a  therapeutic  target 
in HCC [3,95,96]. 
 
Obesity is another important contributing factor for the 
development  of  HCC  [97].  The  important  role  of 
Ras/Raf/MEK/ERK  signaling  has  also  been  suggested 
for  HCC  progression  in  obese  patients.  A  possible 
explanation  for  risk  associated  between  obesity  and 
HCC comes from the study of Saxena et al., which for 
the  first  time  demonstrated that  leptin,  a key  molecule 
involved in the regulation of energy balance and body 
weight control, promotes HCC growth and invasiveness 
through  activation  of  Ras/Raf/MEK/ERK  signaling 
[98].  
 
Other well known risk factors for HCC such as hepatitis 
B  and  C  viruses  (HBV  and  HCV)  also  utilize  the 
Ras/Raf/MEK/ERK  pathway 
the  control  of 
hepatocyte  survival  and  viral  replication  [99].  Among 
the  four  proteins  encoded  by  HBV  genome,  HBx  is 
involved 
activates 
Ras/Raf/MEK/ERK  signaling  cascade  [100].  Among 
HCV components, the core protein has been reported to 
activate  the  Ras/Raf/MEK/ERK  pathway  and  thereby 
might  contribute  to  HCC  carcinogenesis  [101,  102]. 
Therefore, 
the 
Ras/Raf/MEK/ERK  pathway  is  a  novel  therapeutic 
target that could be exploited for the treatment of HCC 
resulting  from  HBV  and  HCV  infection.  microRNAs 
(miRNAs)  may  play  a  key  role  in  regulating  HCV 
translation [103]. Protein translation is regulated by the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways  and  may  be  a  therapeutic  target  for  HCC 
[104].  The  interacting  Wnt/-catenin  pathway  also  has 
effects on HCC [105]. 
 
Mutations at PIK3CA in Human Cancer 
 
The  PI3K  p110  catalytic  subunit  (PIK3CA)  gene  is 
currently  the  most  frequently  mutated  kinase  in  human 
cancer.  PIK3CA  is  mutated  in  approximately  25%  of 
breast,  32%  of  colorectal,  30%  of  endometrial,  27%  of 
brain,  25%  of  gastric,  4%  of  lung  cancers  [106-110] 
(Table  1).  These  mutations  are  clustered  in  small  hot-
spot regions within the helical (E542, E545) and kinase 
(H1047)  domains  [106-110].  The  locations  of  these 
mutations have been recently critically evaluated [110]. 
These  mutations  frequently  result  in  activation  of  its 
kinase activity [110]. Furthermore increased expression of 
the Ras/PI3K/Akt/mTOR pathway also occurs frequently 
in  some  cancers  as  the  PIKC3A  gene  is  amplified  in 
approximately 40% of ovarian cancers [109]. 
 

suggest 

studies 

these 

that 

  
www.impactaging.com 

 

 

 

          206                                          AGING, March 2011, Vol.3 No.3

inactivation  or 

Activation of PI3K/PTEN/Akt/mTOR signaling through 
mutation, 
silencing  of  pathway 
components  occurs  in  various  malignancies,  including 
liver  cancer  [111].  Deregulation  of  this  pathway  has 
clinical  importance  in  HCC.  For  example,  recent  data 
from  genomic  sequence  of  HCC  samples  identified 
mutations  in  PIK3CA  in  50%  of  patients  with  poor 
prognosis,  survival  length  <  3  years  following  partial 
liver resection, and only 10% of the HCC patients with 
a  good  prognosis  had  mutation  in  PIK3CA  [111].  The 
identified  mutations  were  restricted  to  residues  H1047 
in  61.1%,  to  E545  in  33.3%,  and  to  E542  in  5.5%  of 
cases,  and  as  a  consequence  this  result  in  gain  of 
enzymatic  function  and  consequently  in  oncogenic 
activity of PI3K [111].  
 
Mutations at PTEN in Human Cancer 
 
Germline  PTEN  mutations  are  present  in  approximately 
80%  of  patients  with  Cowden  syndrome  [112].  This 
disease,  which  is  also  known  as  multiple  hamartoma 
syndrome,  is  another  familial  syndrome  that  includes 
many different types of cancer conditions including early 
onset  breast  cancer.  Mutations  have  been  reported  to 
occur at PTEN in breast cancer in varying frequencies (5-
21%)  [113,114].  Loss  of  heterozygosity  (LOH) 
is 
probably more common (30%) [114]. Mutations at certain 
residues  of  PTEN,  that  are  associated  with  Cowden’s 
disease,  affect  the  ubiquitination  of  PTEN  and  prevent 
nuclear 
the 
phosphatase  activity  intact  [115].  Inhibition  of  PTEN 
activity  leads  to  centromere  breakage  and  chromosome 
instability [34]. Thus PTEN has diverse activities.  
 
Akt and mTOR phosphorylation are frequently detected 
in ovarian and endometrial cancers. An early occurrence 
in  endometrial  cancer  is  the  loss  of  functional  PTEN 
activity by mutation or other mechanisms, this occurs in 
approximately 40-80% of patients [116]. Since the loss 
of  PTEN  results  in  activation  of  Akt,  that  in  turn  up-
regulates mTOR activity, cancer cells deficient in PTEN 
are thought to be major targets of mTOR inhibitors. 
 
The best evidence that strongly supports the connection 
between  PTEN-suppression  and  liver  carcinogenesis 
comes  from  genetic  studies.  All  mice  with  PTEN-
deficient hepatocytes exhibited liver adenomas and 66% 
of 
these  mice, 
hepatocytes  were  hyperproliferative  and  displayed  an 
abnormal  activation  of  Akt 
[117].  Furthermore, 
although  mutations  in  the  PTEN  gene  rarely  occur  in 
HCC,  frequent  loss  of  heterozygosity  of  PTEN  allele 
has  been  identified  in  20-30%  of  HCC  patients  [118-
121]. In addition, down-regulation of PTEN expression 
may be partly due to PTEN promoter methylation [122]. 

them  developed  HCC  [117].  In 

translocation.  These  mutations 

expression 

PTEN  expression  plays  a  critical  role 
in  HCC 
progression  and  patient’s  outcome.  Patients  with  high 
expression  of  PTEN  had  a  significantly  better  overall 
survival than patients with low PTEN expression [123]. 
As  mentioned  above,  hepatitis  viruses  protect 
hepatocytes from apoptotic cell death by promoting the 
activation  of  Ras/PI3K/Akt/mTOR  survival  pathway 
[124,125].  Among  the  four  proteins  encoded  by  HBV 
genome,  HBx  has  been  reported  to  be  involved  in 
hepatocarcinogenesis.  It  has  been  reported  that  HBx 
expression  downregulated  PTEN 
in 
hepatocytes [125,125]. In contrast, PTEN expression in 
liver  cells  downregulated  HBx-induced  PI3K  and  Akt 
activities  [126].  Therefore,  these  studies  suggest  the 
possible  use  of  PTEN  as  a  target  in  therapeutic 
approaches  for  the  treatment  of  at  least  those  HCC 
caused by HBV infection. 
 
In  some  cancer  settings,  PTEN  and  BRAF  mutations 
appear to interact. Two recent papers have highlighted 
the hypothesis of mutant BRAF- and PTEN-loss-driven 
carcinogenesis in mouse models. In a study by Dhomen 
et al., inducible expression of B-RafV600E was sufficient 
to  induce  multiple  melanocytic  lesions  including  skin 
hyperpigmentation,  dysplastic  nevi  and  melanoma 
these  B-RafV600E  mice 
[127].  Tumor  cells  from 
displayed  both  melanoma  growth  and  melanocyte 
senescence in this system. Approximately 70% of these 
mice  developed  melanomas  that  exhibited  histological 
and  molecular  characteristics  similar  to  that  of  human 
melanoma  and  were  able  to  colonize  the  lungs  in     
nude  mice  [127].  In  contrast,  another  group  of 
researchers generated mice that conditionally-expressed 
melanocyte-specific  B-RafV600E  that  were  only  able  to 
induce  benign  melanocytic  hyperplasias  and  were 
unable  to  progress  any  further  over  a  15-20  month 
period  [128].    However,  B-RafV600E  expression  in  a 
PTEN  gene-silenced  background  led  to  the  production 
of  melanoma  with  100%  establishment,  short  latency 
and  metastasis  to  lymph  nodes  and  lungs.    This 
development  was  prevented  by  the  treatment  of  mice 
with  either  the  mTOR  inhibitor  rapamycin  or  the 
MEK1/2 
inhibitor  (PD0325901).  Moreover,  while 
combination  treatment  with  rapamycin  or  PD0325901 
led  to  the  reduction  of  established  tumors,  upon 
termination  of  drug 
the  melanomas 
reappeared  the  presence  of  drug  resistant  melanoma-
initiating cells in these mice. Overall, these two papers 
further  validated  the  mutant  B-Raf/MEK/ERK  and  the 
PI3K/Akt/mTOR  pathways,  as  promising  therapeutic 
targets in melanoma. 
 
Mutations  and  hemizygous  deletions  of  PTEN  have 
been  detected  in  AML  and  non  Hodgkin’s  lymphoma 
(NHL)  and  other  cancers  [129,130].  Thus  the  PTEN 

treatment 

leave 

  
www.impactaging.com 

 

 

 

          207                                          AGING, March 2011, Vol.3 No.3

indicate, 

promotes 

[131]. 

in 

leukemia  and 

lymphoma, 

In  T-acute 

[129].  Although 

in  vivo  studies 

(T-ALL),  PTEN-downregulation 

gene  is  a  critical  tumor  suppression  gene,  frequently 
mutated in human cancer.  
 
Alterations of PTEN Expression in Human Cancer 
 
Phosphorylation  (inactivation)  of  PTEN  has  been 
associated with increased Akt-activity. Although many 
groups  have  investigated  the  PTEN-phosphorylation 
status 
its  relevance 
concerning  Akt-activation  is  still  not  clear  [129-133]. 
PTEN phosphorylation as well as low or absent PTEN 
expression has been observed in AML.  
 
Furthermore,  the  level  of  PTEN  expression  does  not 
always  correlate  with  the  degree  of  phosphorylation     
of  Akt 
the  picture  concerning      
PTEN-inactivation and corresponding Akt-activation is 
not  clear, 
that  PTEN 
leukemogenesis.  PTEN-
dysregulation 
deficient hematopoietic stem cells display dysregulated 
cell  cycle  progression,  and 
the  mice  develop  a 
myeloproliferative  disease  which  leads  to  leukemic 
lymphoblastic 
transformation 
leukemia 
is  also 
closely  correlated  with  Akt-activation  [132,133].  To 
discern the role of PTEN for Akt-activation, it may be 
useful to exclude concomitant causes for Akt-activation 
such  as  mutant  upstream  targets  and  to  include  the 
investigation of regulators of PTEN such as c-Myc and 
Notch/Hes1 [132,133]. 
 
PTEN  promoter  methylation 
low  PTEN 
expression  [134].  In  one  study,  26%  of  primary  breast 
cancers had low PTEN levels that correlated with lymph 
node metastases and poor prognoses [135].  
 
Other  mechanisms  important  in  the  regulation  of  PTEN 
are  miRNAs.  Certain  miRNAs  have  been  shown  to 
regulate  PTEN  protein  expression.  mi-214  induces  cell 
survival  and  may  contribute  to  oncogenesis  and  drug 
resistance  (see  below)  by  binding  the  3’untranslated 
region (3’UTR) of PTEN which prevents PTEN mRNA 
translation  and  leads  of  overexpression  of  downstream 
Akt [136]. 
 
Mutations  at  SHIP  Phosphatase  in  Human  Cancer 
 
The  SHIP-1  phosphatase  has  been  implicated  as  a 
suppressor  of  hematopoietic 
it 
basically  can  prevent  Akt-activation  [137].  SHIP-1-
deficient  mice  develop  a  myeloproliferative  disease 
[138] and an inactivating point mutation (SHIP V684E) 
has been observed in approximately one of thirty AML 
cases [137]. Also another mutation,  SHIP Q1154L,  has  

transformation  as 

leads 

to 

by 

activated 

genetic  mutations, 

been observed in AML, but was even less frequent (1 of 
192 cases) [138]. Though some studies confirmed, that 
SHIP-1 is a leukemia suppressor [137,138] it is unlikely 
that  SHIP1  mutations  are  a  frequent  cause  of  Akt-
activation in AML. Disruption of PTEN or SHIP activity 
by various genetic mechanisms could have vast effects on 
different  processes  affecting  the  sensitivity  of  different 
cancers to various therapeutic approaches. 
 
Mutations of AKT in Human Cancer 
 
The roles that Akt plays in cancer are complex. Akt can 
be 
genome 
amplifications  and  more  commonly  by  mutations  in 
upstream signaling components. Amplification of Akt-2 
was  observed  in  human  ovarian  carcinomas  [139]. 
Increased  levels  of  Akt  are  detected  in  carcinomas  of 
the breast, ovary and prostate and are associated with a 
poorer prognosis in comparison with tumors that do not 
display increased levels of expression. Akt is a member 
of a multi-gene family that consists of AKT1, AKT2 and 
AKT3. AKT1 has been reported to be mutated in some 
breast, colorectal, melanoma and ovarian cancers [140-
142]  (see  below).  AKT2  is  not  mutated  frequently  in 
human  cancer.  AKT2  is  amplified  in  certain  cancers 
(e.g., 12.1% ovarian and 2.8% breast carcinomas) [142]. 
A  recent  report  documents  the  mutation  of  AKT3  in 
some melanoma samples [143].  
 
AKT1 is mutated in 2 to 8% of breast, 6% of colorectal 
and  2%  of  ovarian  cancers  samples  examined  in  one 
study  [140].  This  study  documented  an  Akt  mutation 
that  results  in  a  glutamic  acid  (E)  for  a  lysine  (K) 
substitution at amino acid 17 (E17K) in the PH domain. 
Cells with this AKT1 mutation have not been observed 
to have mutations at PIK3CA; a similar scenario is also 
frequently  observed  with  RAS  and  BRAF  mutations 
[144].  This  AKT1  mutation  alters  the  electrostatic 
interactions  of  Akt-1  which  allows  it  to  form  new 
hydrogen  bonds  with  the  natural  PtdIns  ligand  [140]. 
The  PH  domain  mutation  confers  many  different 
properties to the AKT1 gene. Namely the mutant AKT1 
gene has: 1) an altered PH domain conformation, 2) is 
constitutively-active,  3)  has  an  altered  cellular 
distribution  as  it  is  constitutively-associated  with  the 
cell  membrane,  4)  morphologically  transforms  Rat-1 
tissue  culture  cells  and  5)  interacts  with  c-Myc  to 
induce  leukemia  in  E-Myc  mice  (E  =  Enhancer  of 
immunoglobulin    gene,  Myc  =  Myc  oncogene 
originally  isolated  in  avian  myelocytomatosis  virus) 
[140].  This  PH  domain  mutated  AKT1  gene  does  not 
alter  its  sensitivity  to  ATP  competitive  inhibitors,  but 
does  alter  its  sensitivity  to  allosteric  kinase  inhibitors 
[140].   These   results  demonstrate  t hat  targeting  the  

  
www.impactaging.com 

 

 

 

          208                                          AGING, March 2011, Vol.3 No.3

is  often  upregulated 

in  cancer  cells  and 

kinase domain of Akt may not be sufficient to suppress 
the activity of various AKT genes that have mutations in 
the PH domain.   
 
Alterations of Akt Expression in Human Cancer 
 
Akt 
its 
overexpression  is  associated  with  a  poor  prognosis. 
Increased  expression  of  Akt  can  result  from  activating 
PIK3CA  mutations  or  elimination  or  decrease  in  PTEN 
activity.  Elevated  Akt  expression  has  also  been 
associated with the pathology of pancreatic, glioma and 
prostate cancers [145-148].  
 
IGF-1R 
Pancreatic  cancer  cells  have  elevated 
expression and it is well known that Akt regulates IGF-
1R  expression  [149].  This  Akt  effect  on  IGF-1R  has 
been suggested to be responsible for the invasiveness of 
pancreatic  cancer  cells.    Active  Src  can  also  activate 
Akt,  and  both  Src  and  Akt  up-regulate  IGF-1R 
expression in this cancer. It has been demonstrated that 
IGF-I is expressed in the surrounding stromal cells but 
not in the cancer cells. This IGF-1 expression may serve 
as  a  paracrine  growth  factor  to  activate  the  IGF-1R 
pathway  and  the  downstream  Ras/PI3K/Akt/mTOR 
pathway in pancreatic cells.  
 
Cyclooxygenase-2 (COX-2) is expressed at high levels 
in  some  primary  endometrial  tumors  and  is  associated 
with an aggressive phenotype [150]. Akt is elevated and 
PTEN is often mutated in these cancers.  Recently, NF-
B activation has been shown to have oncogenic effects 
important  in  the  control  of  apoptosis,  cell  cycle, 
differentiation  and  cell  migration.    Akt  may  exert  its 
effects  through  the  NF-B  pathway  and  COX-2  is  the 
regulator  of  this  pathway.    Akt  regulates  COX2  gene 
and  protein  expression  in  endometrial  cancers.  This 
study  was  undertaken  to  examine  the  involvement  of 
Akt in the regulation of NF-B and COX-2 [150]. The 
expression  of  both  inhibitor  of  NF-B  (IB)  and 
phosphorylated  IB  were 
the  cells 
containing mutant PTEN genes.  In contrast, there was 
no difference in NF-B protein abundance between the 
cell  lines,  which  differed  in  PTEN  gene  status.  IB 
phosphorylation by the PI3K pathway was inhibited by 
the PI3K inhibitors Wortmannin and LY294002. There 
was less NF-B nuclear activity, less COX-2 expression 
and  more  apoptosis  after  inhibition  of  the  PI3K 
pathway.  Dominant  negative  (DN)  Akt  blocked  IB 
phosphorylation  and  decreased  COX-2  expression.  In 
contrast, 
introduction  of  constitutively-active  Akt 
induced  IB  phosphorylation  and  up-regulated  COX-2 
expression. 
 

increased 

in 

that 

lead 

to 

  
www.impactaging.com 

 

 

 

           209                                          AGING, March 2011, Vol.3 No.3

invasiveness.  COX-2       

When PTEN is mutated, Akt signals via the NF-B/IB 
pathway  to  induce  COX-2  expression  in  endometrial 
cancer  cells.  COX-2  can  inhibit  apoptosis,  increase 
angiogenesis,  and  promote 
also  promotes  inflammation/immunosuppression  and 
conversion  of  procarcinogens  into  carcinogens  that 
contribute to tumorigenesis and a malignant phenotype. 
This  study  demonstrated  that  Akt  signals  via  the  NF-
B/IB  pathway  to  induce  COX2  gene  and  protein 
expression in endometrial cancer [150]. 
 
Elevated  Akt  activity  can  also  result  in  increased 
phosphorylation  of  mTOR.  mTOR  was  found  to  be 
phosphorylated  in  AML  blasts,  along  with  its  two 
downstream  substrates,  p70S6K  and  4EBP-1,  in  a 
PI3K/Akt-dependent fashion [151]. Nevertheless, others 
failed  to  detect  any  relationship  between  PI3K/Akt 
signalling  upregulation  and  p70S6K  phosphorylation  in 
AML  primary  cells  [152].  This  might  occur  via  the 
Ras/Raf/MEK/ERK  pathway  activating  mTOR  via  
ERK  phosphorylation  [152].  The  Ras/Raf/MEK/ERK 
pathway  is  frequently  activated  in  AML  [153].  Thus 
treatment  of  AMLs  with  Raf  and  MEK  inhibitors  is 
being activated investigated [3,154,155]. 
 
Akt  is  activated  in  HCC,  which  results  in  enhanced 
resistance  to  apoptosis  through  multiple  mechanisms 
[101,156-158].  As  an  example,  activation  of  the  Akt 
factor-β 
pathway  suppresses 
(TGF-β) 
induced  apoptosis  and  growth-inhibitory 
activity  of  CCAAT/enhancer  binding  protein  alpha 
(CEBP-).  Activation  of  Akt  is  a  risk  factor  for  early 
disease  recurrence and  poor  prognosis  in  patients  with 
HCC [156]. Several mechanisms may be responsible for 
the  activation  of  Akt.  The  high  frequency  of  PIK3CA 
mutations  and/or  its  upregulation  in  patients  with 
shorter  survival  might  be  responsible  for  the  Akt 
hyperactivation  found  in  HCC  with  poor  prognosis 
[118-124].  Selective  epigenetic  silencing  of  multiple 
inhibitors  of  the  Ras  pathway  seems  also  to  be 
responsible  for  the  activation  of  Akt  found  in  HCC 
[111].  Moreover,  impaired  expression  of  PTEN  is 
involved in the regulation of Akt activity. Activation of 
Akt signaling and reduced expression of PTEN has been 
reported  in  40%–60%  of  human  HCC  cases  [111,118-
124].  Some  well  known  risk  factors,  HBV  and  HCV 
seem 
the  Ras/PI3K/PTEN/Akt/mTOR 
pathway  for  the  control  of  hepatocytes  survival  and 
viral  replication  [157,158].  Taken  together,  these  data 
that  Ras/PI3K/Akt/mTOR  pathway  may 
suggest 
represent  an 
the 
treatment  of  HCC  among  patients  with  differing 
etiologies 
this 
aggressive tumor. 
 

the  development  of 

transforming  growth 

therapeutic 

to  utilize 

target  for 

important 

regulates 

Mutations of TSC1/TSC2 Genes in Human Cancer 
 
Mutations in the tumor suppressor genes TSC1 and TSC2 
are associated with a dominant genetic disorder, tuberous 
sclerosis  [42,159].  Patients  with  mutant  TSC  genes 
develop  benign  tumors  (hamartomas).  In  contrast  to 
Cowden’s patients who have germline mutations at PTEN 
and  the  patients  have  a  high  propensity  to  develop 
multiple  malignancies,  TSC  patients  rarely  develop 
multiple  malignant  cancers,  and  if  they  do  develop 
malignant  cancers  they  are  usually  either  renal  cell 
carcinomas (RCCs) or angiomyolipomas [159]. This has 
been  hypothesized  to  result  from  a  lack  of  activation  of 
Akt  in  cells  that  have  mutant  TSC1  or  TSC2  as  mTOR 
activity  is  expressed  at  higher  levels  which  results  in 
inhibition  of  Akt,  perhaps  via  the  effects  of  p70S6K  on 
insulin regulated substrate-1 (IRS1) (Figure 3). TSC1 has 
been  shown  to  be  mutated  in  approximately  15%  of 
urethelial carcinomas (bladder cancers) [159]. 
 
Altered  Expression  of  Components  Downstream  of 
mTOR in Human Cancer 
 
translation  by  phosphorylating 
mTOR 
components  of 
the  protein  synthesis  machinery, 
including  p70S6K  and  4E-BP1  (eukaryotic  initiation 
factor  4E-binding  protein  1) 
[160,161].  p70S6K 
phosphorylates the 40S ribosomal protein, rpS6, leading 
to active translation of mRNAs [4]. In contrast, 4E-BP1 
phosphorylation  by  mTORC1  on  several  amino  acidic 
residues (S37; T46; S65; T70) results in the release of 
the eukaryotic initiation factor 4E (eIF4E) [5]. mRNAs 
differ  in  their  ability  to  be  translated;  the  length  and 
sequence of the 5’ UTR largely dictates the efficiency 
with which an mRNA transcript will be translated. Most 
mRNAs  contain  short,  unstructured  GC-poor  5’  UTRs 
and are efficiently translated. In contrast, long, GC-rich 
sequences in the 5’ UTR often hinder the ability of the 
eIF-4E  complex 
initiate 
translation at the start codon [4,19,35]. These are called 
weak  mRNAs  as  previously  discussed.  Consequently, 
under  normal  circumstances  these  mRNAs  are  not 
efficiently 
translated,  and  are  considered  “weak” 
[4,19,35].  However,  upon  Akt-mediated 
mRNAs 
activation of mTOR, these latter mRNAs are highly and 
disproportionately  translated.  Interestingly,  many  of 
these  weak  mRNAs  molecules  encode  oncogenic 
proteins involved in cell proliferation or survival (e.g., 
c-Myc,  Mcl-1,  cyclin-D,  VEGF  and  survivin).  These 
oncogenic mRNAs are therefore tightly regulated at the 
translation level and their accumulation in cancer cells 
strongly contributes to the malignant phenotype.  
 
Several  key  proteins  that  are  overexpressed  as  a 
consequence of mTOR activation include: c-Myc [162-

to  efficiently  scan  and 

in  cell  growth 

by 

both 

is  amplified 

involved 
regulated 

164],  cyclin  D1  [164],  and  VEGF  [165]  and  others.  
Cyclin  D1  has  been  reported  to  be  overexpressed  in 
prostate cancer xenografts and metastases [166], while 
early stage prostatic lesions possess much lower levels 
of  the  protein  [167].  A  number  of  reports  support  the 
notion  that  mTOR  signaling  is  a  prominent  feature  of 
cancer progression and aging, as recurrent tumors have 
altered expression of a number of molecular targets of 
rapamycin including the above mentioned genes which 
encode  “weak”  mRNAs    [168-171].    Hence  mTOR 
inhibitors such as rapamycin may be effective in cancer 
therapy. 
 
is     
One  central  molecule 
the 
p70S6K  which 
is 
Ras/PI3K/PTEN/Akt/mTOR  and  Ras/Raf/MEK/ERK 
pathways  [4].  The  p70S6K  gene 
in 
approximately 9% of primary breast cancers and elevated 
levels of its mRNA transcripts are found in about 41% of 
the  tumors  [173,174].  It  is  known  that  some  PTEN-
deficient  cells  and  tumors  that  are  purported  to  grow  in 
response  to  activated  Akt  are  hypersensitive  to  mTOR 
inhibitors.  p70S6K  activity 
is  reduced  by  mTOR 
inhibitors in PTEN-deficient cells and transgenic PTEN+/- 
mice [175,176]. 
 
Involvement  of 
the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  Pathways in Hormone-
Independent Prostate Cancer 
 
The  progression  of  prostate  cancer  from  androgen-
dependent to androgen-independent tumors involves the 
alteration of the androgen receptor and/or the activation 
of  pro-survival  pathways,  namely 
the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
signaling cascades [177,178].  Research has shown that 
inhibition of one or both of these pathways has a more 
profound  effect  on  tumor  cell  development  and  death 
making them very attractive as combinational targets in 
prostate cancer therapy.  In the study by Wu et al., cells 
from  the  androgen-dependent  cell  line  LNCaP  were 
able to differentiate into neuroendocrine type cells upon 
androgen  withdrawal  from  the  culture  media  [177].  
This differentiation was marked by a change in cellular 
morphology  and  expression  of  the  chromogranin  and 
neuron-specific enolase (NSE), as well as an increase in 
phosphorylated  ERK  and  Akt.    Inhibition  of  the 
Ras/PI3K/PTEN/Akt/mTOR  pathway  with  the  PI3K 
inhibitor  LY294002 
inhibitor 
Rapamycin 
these 
reduced 
neuroendocrine specific cell markers however the use of 
the  MEK 
effect  [177].    In  another  study,  Nkx3.1;Pten  mutant 
mice  were  used  as  a  preclinical  model  for  the  effects 
that 
inhibition  of  both  Ras/Raf/MEK/ERK  and 

inhibitor  U0126  appeared 

the  mTOR 
expression 

those  of 

and 
the 

of 

to  have  no       

  
www.impactaging.com 

 

 

 

           210                                          AGING, March 2011, Vol.3 No.3

of 

some 

of 

tumors. 

aberrant 

activation 

  In  addition,  activation  of 

Ras/PI3K/PTEN/Akt/mTOR  pathways  would  have  on 
hormone-dependent  and  -independent  prostate  cancer 
growth  [178].  The  Nkx3.1;Pten  mutant  mouse  model 
resembles that of human prostate cancer progression in 
which  spontaneous  PIN  lesions  form  and  progress  to 
adenocarcinomas  and  eventually  hormone  refractory 
tumors  upon  androgen  deprivation.    Treatment  of 
tumors from these  mice both in vivo and in vitro with 
rapamycin  and  the  MEK  inhibitor  PD0325901  were 
able  to  synergistically  decrease  their  respective  target 
pathway’s  activation  more  effectively  and  at  a  lower 
IC50 compared to treatment with each agent alone [179].  
Interestingly,  although  combination  inhibitor  therapy 
was  somewhat  effective  at  reducing  tumor  size  and 
proliferation  in  the  androgen-intact  mouse  model,  the 
highest  reduction  in  tumor  growth  from  therapy  was 
observed  in  the  androgen-deficient  mice  [178].    In 
addition  to  the  mouse  study  these  authors  were  able     
to  show,  using  human  patient  tissue  microarrays,           
that 
the 
Ras/PI3K/PTEN/Akt/mTOR pathway components (Akt, 
mTOR,  p70S6K)  are  frequent  in  progressed  human 
prostate 
the 
Ras/Raf/MEK/ERK  pathway  coincides  with  a  high 
percentage  of  these  tumors  as  well,  suggesting  that 
combination  inhibitor  treatment  along  with  hormone 
ablation  could  prove  useful  in  human  prostate  cancer 
therapies [178]. 
 
Interactions of p53 and the Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways 
 
 Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways 
suppressor  p53.  Furthermore  p53  activity  is  likewise 
regulated 
and 
Ras/PI3K/PTEN/Akt/mTOR pathways. p53 is a critical 
tumor  suppressor  gene  which  encodes  a  transcription 
factor that is frequently mutated in human cancer [179-
195].  P53  regulates  the  transcription  of  many  genes 
whose protein products play critical roles in cell cycle 
progression,  apoptosis,  senescence,  quiescence  and 
aging.  p53  is  often  activated  after  chemotherapeutic 
drug  treatment  and  DNA  damage  [182,183,193-195] 
There  are  complex  interactions  between  p53,  DNA 
damage  responses  and  these  two  signaling  pathways 
[180-195]. Akt can phosphorylate MDM-2 which leads 
to its proteasomal degradation and prevents it ability to 
interact  with  and  destabilize  p53  [4].  The  p53  and 
MDM  families  of  genes  are  critically  involved  in  the 
response  to  DNA  damage  [183-185],  apoptosis  [185], 
senescence  [186],  metastasis  [188],  autophagy  [190], 
chemosensitivity 
aging 
[179,181,182].  Thus  the  ability  to  fine  tune  these 
pathways  could  significantly  advance  human  health. 

Ras/Raf/MEK/ERK 

regulated  by 

are  often 

[191,195] 

tumor       

cellular 

and 

the 

by 

the 

MDM-2  inhibitors  such  as  Nutlin-3A  increase  p53 
stability  [179].  p53  can  affect  the  transcription  of  the 
PTEN and other important gene involved in cell cycle 
regulation  (e.g.,  p21Cip-1),  apoptosis  (e.g.,  Bax,  Noxa, 
Puma)  and  cellular  senescence  [e.g.,  Yippee-like-3 
(YPEL3)], [180,184-186,192]. Thus reactivation of p53 
expression  could  enhance  PTEN  gene  expression  and 
hinder activation of Akt.  
 
The  Ras/Raf/MEK/ERK  pathway  can  regulate  p53 
activity  and  p53  can  also  induce  the  activity  of  key 
components  of  this  pathway  [196-198].  ERK  can 
phosphorylate  p53  and  alter  its  activity.  Moreover, 
chemotherapeutic drugs such as doxorubicin can induce 
the p53 activity that in turn can activate the expression 
of  the  discoidin  domain  receptor  (DDR)  which  can 
induce  Ras  and  the  downstream  Ras/Raf/MEK/ERK 
and Ras/PI3K/PTEN/Akt/mTOR pathways [196-198].  
 
In  certain  scenarios,  increased  p53  expression  after 
chemotherapeutic drug treatment may lead to increased 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways  activation,  resulting  in  an  undesired  pro-
proliferative  effect  [195].  This  may  occur  in  certain 
cancer  initiating  cells  (CICs)  and  be  a  component  of 
their  inherent  drug  resistance.  In  addition,  Akt  has 
critical  roles  in  regulation  of  cell  cycle  progression 
[199-202]  Thus  in  those  therapeutic  scenarios  where 
increased p53 activity is desired, it may also be prudent 
to  also  consider  treatment  with  either  a  Raf  or  MEK 
inhibitor 
to  decrease 
this  pro-
proliferative pathway.  
 
Novel  Roles  of 
the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  Pathways  in  Cancer 
and Aging 
 
In  the  previous  sections,  we  have  discussed  the 
mechanisms  of  activation  of  the  Ras/Raf/MEK/ERK 
and  Ras/PI3K/PTEN/Akt/mTOR  pathways  in  human 
cancers, 
based 
mechanisms.  Recently  the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  pathways  have  been 
shown  to  have  roles  in  cancer  stem  cells,  senescence, 
aging  and  sensitivity  to  targeted  therapy  [203-245]. 
These  additional  functions  of  these  pathways  expand 
their important in human health.    
 
An  area  of  intense  interest  in  cancer  biology  is  the 
cancer 
to  as  the  cancer  initiating  cell  (CIC)  [203-211].  The 
concept 
and 
Ras/PI3K/PTEN/Akt/mTOR  pathways  serve  as  key 
pathways  in  regulating  CIC  survival  is  beginning  to 
emerge.  CICs  have  unique  properties  as  they  can  be 

Ras/Raf/MEK/ERK 

the  activation  of 

by  mutational 

predominantly 

appropriately 

cell,  more 

stem 

that 

the 

referred                

  
www.impactaging.com 

 

 

 

           211                                          AGING, March 2011, Vol.3 No.3

the  myeloproliferative  disorder 

both  quiescent  and  also  resistant  to  chemotherapeutic 
and  hormonal  based  drugs  [203].  However,  under 
certain conditions, they resume proliferation and hence 
should  be  potentially  susceptible  to  Ras,  Raf,  MEK, 
PI3K, Akt or mTOR inhibitors.  
 
The  PTEN  gene  has  been  shown  to  exert  effects  on 
CICs, especially in hematopoietic and breast cells [204-
209].  In  conditional  PTEN  knock-out  mice,  upon 
inactivation  of  PTEN,  there  is  a  transient  increase  in 
hematopoietic  CICs  and  a  myeloproliferative  disease 
develops  and  the  mice  subsequently  develop  leukemia 
after  4-6  weeks  [204].  If  the  mice  are  treated  with 
rapamycin, 
and 
leukemia are prevented. The initial leukemic CICs that 
arise after conditional PTEN deletion by themselves are 
not  able  to  induce  leukemia  upon  transfer  into  severe 
combined  immunodeficiency  (SCID)-recipient  mice, 
but if the leukemic CICs were derived from the PTEN-
conditional  mice  that  had  developed  leukemia,  they 
were  able  to  transfer  leukemia  to  the  SCID-recipient 
mice, which could be prevented by rapamycin treatment 
[204].  Also  the  normal  hematopoietic  stem  cells  from 
the PTEN-conditional knock-out mice could repopulate 
the  hematopoietic  cell  component  of  irradiated  mice 
treated  with  rapamycin  indicating  that  it  is  possible  to 
selectively eliminate leukemic CICs. 
 
PTEN  also  plays  important  roles  in  breast  CICs 
[205,206]. If PTEN is mutated, Akt phosphorylates and 
inactivates  glycogen  synthetase  kinase  3  (GSK-3) 
which in turn regulates the activity of the Wnt/-catenin 
pathway [Figure 3], as -catenin is not phosphorylated 
by GSK-3 and not degraded. -catenin can    localize 
to 
to  Akt-mediated 
phosphorylation at S552 and exert its effects. -catenin 
can  then  promote  the  expression  of  many  genes        
such  as  cyclin  D,  c-Myc,  SALL4  and  peroxisome     
proliferator-activated  receptor-  (PPAR)  which  are 
important 
and  EMT.  The 
Ras/PI3K/PTEN/Akt/mTOR  pathway  performs  key 
roles  in  the  regulation  of  the  size  of  the  Aldefluor-
positive cell population that are enriched in breast CICs. 
Treatment with the Akt inhibitor perifosine was able to 
target these cells both in in vitro and xenograft models 
[206]. In contrast, the chemotherapeutic drug docetaxel 
was  unable  to  target  the  Aldefluor-positive  cells  and 
these  cells  were  not  sensitive  to  mTOR  inhibitors, 
suggesting that the mTOR pathway was not involved in 
these breasts CIC. The studies by Korkaya et al. [206] 
indicate that targeting some breast CICs with perifosine 
may eliminate these cells that are responsible for tumor 
reappearance.  Other  studies  have  shown  that  breast 
CICs are resistant to chemotherapeutic drugs [212-214].  
 

the  nucleus,  perhaps  due 

survival 

cell 

in 

We  have  observed  that  some  drug  resistant  breast    
cells  that  express  properties  similar  to  CICs  display 
elevated  activation  of  the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR signaling cascades and that 
CICs can be isolated from these cell populations [215-
217].  Our  recent  data  suggests  these  CICs  are  more 
sensitive to MEK and mTOR inhibitors than either the 
parental  or  drug  resistant  cells  from  which  they  were 
derived  [215].  Targeting  the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/mTOR  pathways  could  be  very 
important in terms of CIC elimination. 
 
Involvement  of 
the  Ras/Raf/MEK/ERK  and 
PI3K/PTEN/Akt/mTOR  Pathways  in  Suppression 
Cellular Senescence and Premature Aging 
 
The  Ras/Raf/MEK/ERK  and  PI3K/PTEN/Akt/mTOR 
pathways  play  key  roles  in  regulation  of  diverse 
processes  ranging  from:  autophagy  DNA  damage 
responses,  cellular  senescence  and  aging  [217-237] 
Treatment of cells induced to undergo senescence with 
MEK,  PI3K  and  mTOR  inhibitors  will  prevent  the 
induction  of  cellular  senescence  and  aging  [219-221]. 
These  experiments  have  led  to  innovative  hypothesis 
that  cellular  senescence  results  from 
the  hyper-
activation of proliferative pathways. Drugs used to treat 
diabetes (e.g., Metformin) or inhibit signal transduction 
pathways (e.g., Raf, MEK, PI3K, mTOR inhibitors) can 
inhibit  cellular  proliferation  and  cellular  aging  [229-
234].  Similar  effects  on  the  prevention  of  cellular 
senescence  were  observed  with  Resveratol,  the  active 
component  contained  in the  skins  of  red grapes  which 
was  shown 
inhibit  mTOR  and  cellular 
senescence  [229,230].  Additional  studies  have  shown 
that the commonly-prescribed diabetes drug Metformin 
will  also  inhibit  mTOR  and  prevent  cellular  aging 
[234]. 
and 
PI3K/PTEN/Akt/mTOR  pathways  interact  to  regulate 
the  activity  of  mTOR  and  downstream  components  of 
this pathway which are critical for both mRNA stability 
and protein translation, it is believed that by inhibiting 
some  of  these  key  pathways,  it  may  be  possible  to 
prevent cellular aging (See Figures 1-3). 
 
CONCLUSIONS 
 
Over  the  past  25  years,  there  has  been  significant 
progress 
the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
cascades in promoting cell growth, regulating apoptosis, 
chemotherapeutic  drug  resistance  and  more  recently, 
cellular  senescence  and  aging.  Initial  seminal  studies 
performed in the late 70’s and early 80’s elucidated that 
oncogenes  were  present  in  the  genomes  of avian and  

the  Raf/MEK/ERK 

involvement  of 

in  elucidating 

to  also 

the 

Since 

both 

  
www.impactaging.com 

 

 

 

           212                                          AGING, March 2011, Vol.3 No.3

murine  retroviruses.  Many  of  the  viral  oncogenes: 
ErbB, Fms, Ras, PI3K, Akt, Src, Abl, Raf, Fos, Jun, Ets 
and  NF-B  (Rel)  were  subsequently  identified  as 
cellular  genes  which  in  some  cases  were  captured  by 
retroviruses. Now we know that these cellular genes are 
frequently  abnormally  regulated  in  human  cancer. 
Furthermore mutations in human cancer often occur in 
upstream  receptor  genes  such  as  EGFR,  HER2,  Flt-2, 
PDGFR,  FMS,  as  well  as  chromosomal  translocations 
(e.g., BCR-ABL, TEL-PDGFR) that serve to activate the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways which have been discussed as playing critical 
roles  in  cellular  proliferation  in  this  review.    Hence    
the  Ras/Raf/MEK/ERK  and  Ras/PI3K/Akt/mTOR 
pathways  are  important  therapeutic  targets.  Both  of 
these  pathways  also  interact  with  the  p53  and  Wnt 
pathways, which also play critical roles in regulation of 
cell  growth,  aging,  CICs  and  metastasis.  Specific  Raf, 
MEK,  PI3K,  Akt,  mTOR  and  Mdm-2  inhibitors  have 
been  developed  and  represent  promising  therapies  for 
cancer  and  other  proliferative  diseases 
including 
premature aging.  
 
Scientists  and  clinicians  often  have  an  intentionally 
narrow view of a particular topic. For example, cancer 
researchers  predominately  consider  that  Raf,  MEK, 
PI3K,  Akt  and  mTOR  inhibitors  will  suppress  the 
growth of malignant cancer cells. Yet MEK and mTOR 
and other inhibitors may also be useful in the treatment 
of  diseases  and  disorders  where  there  is  abnormal 
cellular  proliferation.  Recent 
reports  have  also 
demonstrated 
the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways  may  prevent 
induction  of  cellular 
senescence  and  aging.  Clearly,  this  later  topic,  aging, 
greatly  enhances  the  potential  clinical  uses  of  these 
targeted 
the 
Ras/Raf/MEK/ERK  and  Ras/  PI3K/PTEN/Akt/mTOR 
pathways  are  prime  therapeutic  targets  for  diverse 
human diseases as well as aging. 
 
Cancer therapy is often complex as there are relatively 
few  cancers  which  proliferate  in  response  to  a  single 
mutation  preventing  them  from  being  treated  with  a 
mono-specific  drug.  One  exception  is  the  use  of  the 
drug  Gleevec  (Imatinb)  for  the  treatment  of  chronic 
myeloid  leukemia  (CML).  Although  even  with  this 
therapeutic  approach,  resistance  develops.  Scientists 
and  clinicians  have  developed  newer  BCR-ABL 
inhibitors  (e.g.,  Dasatinib,  Nilotinib,  Bosutinib)  which 
can  reduce  resistance  which  has  also  resulted  in  more 
through  analysis  and  understanding  of  how  the  BCR-
ABL  kinase  functions  and  resistance  can  arise  by 
additional  genetic  mutations.  These  studies  on  BCR-
ABL 
for 

inhibitors  have  also  paved 

therapeutic  drugs. 

suppression 

conclusion, 

the  way 

the 

that 

the 

of 

In 

development  of  more  effective  inhibitors  for  other 
oncogenes. 
 
It is possible that activation of the Ras/Raf/MEK/ERK 
and  Ras/PI3K/PTEN/Akt/mTOR  survival  pathways  by 
additional  mutations 
in  upstream  oncogenes  may 
replace the tumor’s initial oncogene addition. This may 
complicate  therapy  as  the  tumor  may  no  longer  be 
responsive  to  treatment  with  a  single  inhibitor  which 
targets the original oncogene responsible for malignant 
transformation  as 
the  cells  now  have  additional 
downstream signalling pathways activated. In addition, 
the  tumor  cells  may  acquire  subsequent  mutations 
which  make  them  resistant to  inhibitors  that  target  the 
original activated oncogene. Such mutations may occur 
in the original activated oncogene or in additional genes 
which  are  critical  in  anti-apoptotic  survival  cascades. 
These  observations  document  the  need  for  further 
elucidation  of  mechanisms  of  inhibitor  resistance  as 
well as the development of additional inhibitors which 
target  either  the  mutated  oncogene  or  other  genes 
activated in the resistant cells. 
 
The activation of multiple signalling pathways by many 
oncogenes illustrates the need for the targeting of more 
than  one  signalling  pathway.  Although  one  inhibitor 
which  targets  one  molecule  in  one  pathway  may 
initially  appear  to  be  effective  in  inhibiting  tumor       
cell growth, the cell may adapt and be able to survive 
due  to  the  activation  of  an  additional  signalling 
pathway.  Although 
the  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  pathways  have  distinct 
effects  on  cell  proliferation,  they  have  many  common 
downstream  targets  that  may  be  able  to  function  in 
promoting survival in the absence of the corresponding 
functional  pathway.  In  some  cases  resistance  to  small 
molecule  inhibitors  may  be  due  to  the  activation          
of  an  additional  pathway  that  also  serves  to  promote 
survival (e.g., PIK3CA and HRAS mutations can confer 
resistance 
targeted 
therapeutics such as Erbitux and others) [238-245]. 
 
Most cancers are more complex and often the genes and 
events  involved  are  either  not  known  or  difficult  to 
counterbalance. Chemotherapy and radiotherapy can be 
effective  in  the  treatment  of  certain  tumors,  however, 
often  cancers  become  resistant  to  these  approaches, 
perhaps  due  to  the  emergence  of  CICs  [203,215-217]. 
Thus  scientists  and  clinicians  have  endeavored  to 
develop  more  specific 
target  key 
pathways involved in cancer growth. In this respect, the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/mTOR/Akt 
pathways  represent  key  therapeutic  targets  as  they  are 
often  dysregulated  by  various  mutations  in  cancer  and 
these  cascades  control  the  activities  of  many  proteins 

inhibitors  and  other 

to  MEK 

therapies 

that 

  
www.impactaging.com 

 

 

 

           213                                          AGING, March 2011, Vol.3 No.3

targets  (easily 

the  cancer.  Second,  although 

critical  for  cell  growth  and  metastasis.  In  fact,  these 
pathways  are  already  being  targeted  in  certain  cancer 
patients.  However,  usually  the  cancer  patients  being 
treated  with  inhibitors  that  target  these  cascades  have 
diseases  that  often  have  poor  prognoses.  That  being 
said,  what  are  the  pros  and  cons  of  targeting  these 
pathways?  Let  us  first  consider  the  positive  aspects  of 
targeting  these  pathways.  First,  these  pathways  are 
frequently  activated  in  human  cancer,  thus  in  many 
cases, targeting the cascades will suppress cell growth, 
in  the  absence  of  knowing  the  precise  mutation(s) 
responsible  for 
the 
biochemical  interactions  of  these  pathways  are  quite 
complex, there is quite a bit of knowledge of how these 
pathways function. Third, some inhibitors which target 
key components in this pathway (e.g., rapamycin which 
targets mTOR) have undergone extensive evaluation in 
humans  as  they  have  been  used  to  prevent  allograft 
rejection  in  kidney  and  other  transplant  patients  for 
many  years.  Fourth,  targeting  these  pathways  may 
prevent aging and cellular senescence.  
 
Now,  let  us  summarize  some  of  the  cons  of  targeting 
these  pathways.  First,  an  obvious  problem  results     
from  these  pathways  controlling  the  expression  of   
many  downstream 
thus  inhibiting  these  pathways  will  be  detrimental  in 
certain  cells,  unless  it  is  possible  to  deliver  the    
inhibitor  to  specifically  the  cancer  cell.  Second,  the 
Ras/Raf/MEK/ERK  and  Ras/PI3K/PTEN/Akt/mTOR 
pathways cross regulate each other and other pathways 
including  the Wnt/-cateinin  pathway  which  is  critical 
for many aspects of cellular growth and differentiation 
including 
the  EMT.  The  Ras/Raf/MEK/ERK  and 
Ras/PI3K/PTEN/Akt/mTOR  pathways  also  regulate 
other  pathways  which  have  not  been  discussed  in  this 
manuscript.  These  other  pathways 
the 
Jak/STAT,  NF-κB  and  transforming  growth  factor- 
(TGF-) pathways which can be directly and indirectly 
regulated by ERK and Akt phosphorylation [62].  In this 
regards  there  will  be  a  Ying-Yang  effect,  when  one 
cascade  is  inhibited,  components  of  the  other  pathway 
could be deregulated. Third, inhibitors that target these 
pathways are often cytostatic and not cytotoxic, that is 
somewhat logical as if these inhibitors were cytotoxic, 
there  would  be  massive  toxicity  problems.  To  get 
around this problem, inhibitors targeting these pathways 
could  be  combined  with  cytotoxic  chemotherapeutic 
drugs  or  radiation  therapy  that  affects  the  rapidly 
growing  cancer  cell.  In  summary,  the  Ras/Raf/MEK/ 
ERK  and  Ras/PI3K/PTEN/Akt/mTOR  cascades  are 
complex,  interacting  pathways  playing  key  roles  in 
normal and malignant cell growth. These pathways are 
frequently  activated  by  mutations  in  human  cancer. 
They  represent  key  therapeutic  targets  for  cancer  and 

include: 

in 

the  1000’s),       

and 

3‐kinase/Akt/mammalian 

JA.  The  emerging  role  of 
target 

various  other  diseases  as  well  as  the  prevention  of 
aging. 
 
ACKNOWLEDGEMENTS 
 
This  work  was  supported  in  part  by  grants  from: 
Fondazione del Monte di Bologna e Ravenna, MinSan 
2008  “Molecular  therapy  in  pediatric  sarcomas  and 
leukemias against IGF-1 receptor system”, PRIN 2008 
and FIRB 2010 (RBAP10447J) to AMM. 
 
REFERENCES 
 
1.  Casar  B,  Pinto  A,  Crespo  P.  ERK  dimmers  and  scaffold 
proteins:  unexpected  partners  for  a  forgotten  task.  Cell  Cycle. 
2009; 8:1007‐1013.  
2. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, 
Basecke J, et al. Targeting Survival Cascades Induced by Activation 
of  Raf/Raf/MEK/ERK,  PI3K/PTEN/Akt/mTOR 
Jak/STAT 
pathways  for effective  leukemia  therapy. Leukemia. 2008;22:708‐
722.  
3. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, 
Ove  R  et  al.  Emerging  Raf  Inhibitors.  Exp  Opin  Emerging  Drugs 
2009;14:633‐648.  
4. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, 
the 
Ognibene  A,  McCubrey 
phosphatiylinositol 
of 
rapamycin  signaling  network 
in  normal  myelopoiesis  and 
leukemogensis. Biochim Biophys Act. 2010;1803:991‐1002.  
5. Korotchkina  LG,  Leontieva  OV,  Bukreeva  EI,  Demidenko  ZN, 
Gudkov AV, Blagosklonny MV. The choice between p53‐induced 
senescence and quiescence is determined in part by the mTOR 
pathway.  Aging. 2010; 2:344‐352.  
6. Safina  AF,  Varga  AE,  Bianchi  A,  Zheng  Q,  Kunnev  D,  Liang  P, 
Bakin  AV.  Ras  alters  epithelial‐mesenchymal  transition 
in 
response  to  TGFbeta  by  reducing  actin  fibers  and  cell‐matrix 
adhesion. Cell Cycle. 2009;8:284‐298.  
7. Downward  J.  Targeting  Ras  signaling  pathways  in  cancer 
therapy. Nature Reviews Cancer. 2003;3:11‐22.  
8. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue 
K.  Insulin  receptor  substrate‐1/SHP‐2  interaction,  a  phenotype‐
dependent  switching  machinery  of  insulin‐like  growth  factor‐I 
signaling  in  vascular  smooth  muscle  cells.  J  Biol  Chem.  2004; 
279:40807‐40818.  
9. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf‐1 to 
the plasma membrane for activation by tyrosine phosphorylation. 
EMBO J. 1995;14:3136‐145. 
10.  Lefloch R, Pouyssegur J, Lenormand P. Total ERK1/2 activity 
regulates cell proliferation. Cell Cycle. 2009;8:705‐711.  
11.  Knizetova  P,  Ehrmann  J,  Hlobilkova  A,  Vancova  I,  Kalita  O, 
Kolar Z, Bartek J. Autocrine regulation of glioblastoma cell cycle 
progression,  viability  and  radioresistance  through  the  VEGF‐
VEGFR2 (KDR) interplay. Cell Cycle. 2008;7:2553‐2561.  
12.  Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell 
proliferation  and  cell  death:  Is  subcellular  localization  the 
answer? Cell Cycle. 2009; 8:1168‐1175. 
13.  Xing J, Ginty DD, Greenberg ME.  Coupling of the Ras‐MAPK 
pathway  to  gene  activation  by  Rsk2,  a  growth  factor  regulated 
CREB kinase. Science. 1996;273:959‐963.  

  
www.impactaging.com 

 

 

 

           214                                          AGING, March 2011, Vol.3 No.3

14.  Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, Singh‐Gupta V, 
Qin J, Ruan H, Comb MJ, Tzivion G. Identification of novel in vivo 
Raf‐1  phosphorylation  sites  mediating  positive  feedback  Raf‐1 
regulation  by  extracellular  signal‐regulated  kinase.  Mol  Biol  Cell. 
2006;17:1141‐1153.  
15.  Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland 
TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of 
Raf‐1  by  direct feedback  phosphorylation.  Mol Cell.  2005;17:215‐
224.   
16.  Brummer  T,  Naegele  H, Reth  M,  Misawa  Y.  Identification  of 
novel  ERK‐mediated  feedback  phosphorylation  sites  at  the  C‐
terminus of B‐Raf. Oncogene. 2003;22:8823‐8834.  
17.  Catalanotti, F, Reyes G, Jesenberger V Galabova‐Kovacs G, de 
Matos  Simoes  R,  Carugo  O,  Baccarini  M.  A  Mek1‐Mek2 
heterodimer  determines  the  strength  and  duration  of  the  Erk 
signal. Nat Struct Mol Biol. 2009;16:294‐303.  
18.  Davis  RJ.  Transcriptional  regulation  by  MAP  kinases.  Mol 
Reprod Dev. 1995;42:459‐467. 
19.  Martelli  AM,  Evangelisti  C,  Chiarini  F,  McCubrey  JA.  The 
phosphatidylinositol  3‐kinase/Akt/mTOR  signaling  network  as  a 
therapeutic  target  in  acute  myelogenous  leukemia  patients. 
Oncotarget. 2010;1:89‐103.  
20.  Zhao  L,  Vogt  PK.   Hot ‐spot  mutations  in  p110alpha  of 
phosphatidylinositol  3‐kinase  (pI3K):  differential  interactions 
with  the  regulatory  subunit  p85  and  with  RAS.  Cell  Cycle. 
2010;9:596‐600.  
21.  Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of 
the  Akt  proto‐oncogene  product  by  phosphatidylinositol‐3,4‐
bisphosphate. Science. 1997;275:665‐668.  
22.  Coffer 
and 
characterisation of a novel putative protein‐serine kinase related to 
the cAMP‐dependent and protein kinase C families. Eur J Biochem. 
1991;201:475‐481.  
23.  Alessi  DR,  James  SR,  Downes  CP,  Holmes  AB,  Gaffney  PR, 
Reese  CB,  Cohen  P.  Characterization  of  a  3‐phosphoinositide‐
dependent  protein  kinase  which  phosphorylates  and  activates 
protein kinase Balpha. Curr Biol. 1997;7:261‐269.  
24.  Lee  JT,  Steelman  LS,  Chappell  WH,  McCubrey  JA.  Akt 
Inactivates 
to 
chemotherapeutic  drugs  in  advanced  CaP  cells.  Cell  Cycle. 
2008;7:631‐636.   
25.  Du K, Montminy M. CREB is a regulatory target for the protein 
kinase Akt/PKB. J Biol Chem. 1998;273:32377‐32379.  
26.  Brennan  P,  Babbage  JW,  Burgering  BM,  Groner  B,  Reif  K, 
Cantrell DA. Phosphatidylinositol 3‐kinase couples the interleukin‐2 
receptor to the cell cycle regulator E2F. Immunity. 1997;7:679‐689.  
27.  Kane  LP,  Shapiro  VS,  Stokoe  D,  Weiss  A.  Induction  of  NF‐
kappaB by the Akt/PKB kinase. Curr Biol. 1999;9:601‐604.  
28.  Buitenhuis M, Coffer PJ. The role of the PI3K‐PKB signaling 
module  in  regulation  of  hematopoiesis.  Cell  Cycle.  2009;8:560‐
566.  
29.  del Peso L, Gonzalez‐Garcia M, Page C, Herrera R, Nuñez G. 
Interleukin‐3‐induced phosphorylation of BAD through the protein 
kinase Akt. Science. 1997;278:687‐689.  
30.  Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 
Inhibition  of  glycogen  synthase  kinase‐3  by  insulin  mediated  by 
protein kinase B. Nature. 1995;378:785‐789.  
31.  Chalhoub  N,  Baker  SJ.  PTEN  and  the  PI3‐kinase  pathway  in 
cancer. Ann Rev Pathol Mech Dis. 2009;4:127‐150.  

JR.  Molecular 

PJ,  Woodgett 

decreased 

response 

causing 

cloning 

ERK 

in 

Raf/MEK/ERK 

from  mutations 

inactivation  and  hyperactivation  of 

32.  Diaz‐Meco MT. Abu‐Baker S.  The Par‐4/PTEN connection in 
tumor suppression. Cell Cycle. 2009;8:2518‐2522.  
33.  Mahimainathan  L,  Choudhury  GG.  Inactivation  of  platelet‐
derived  growth  factor  receptor  by  the  tumor  suppressor  PTEN 
provides  a  novel  mechanism  of  action  of  the  phosphatase.  J  Biol 
Chem. 2004;279:15258‐15268.  
34.  Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng 
S,  Pagan  J,  Jeffery  J,  Puc  J,  Kumar  R,  Feng  Z,  et  al.  Cell  cycle 
checkpoint  defects  contribute  to  genomic  instability  in  PTEN 
deficient  cells  independent  of  DNA  DSB  repair.  Cell  Cycle. 
2009;8:2198‐2210.  
35.  McCubrey  JA,  Steelman  LS,  Kempf  CR,  Chappell  WH, 
Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke 
J, Maksimovic‐Ivanic D, Mijatovic S, et al. Therapeutic resistance 
resulting 
and 
PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011; In 
Press. 
36.  Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis 
M,  Nowill  AE,  Leslie  NR,  Cardoso  AA,  Barata  JT.  PTEN 
posttranslational 
the 
PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin 
Invest. 2008;118:3762‐3774.  
37.  Gao  T,  Furnari  F,  Newton  AC.  PHLPP:  a  phosphatase  that 
directly dephosphorylates Akt, promotes apoptosis, and suppresses 
tumor growth. Mol Cell. 2005;18:13‐24.  
38.  Damen  JE,  Liu  L,  Rosten  P,  Humphries  RK,  Jefferson  AB, 
Majerus PW, Krystal G.  The 145‐kDa protein induced to associate 
with  Shc  by  multiple  cytokines  is  an  inositol  tetraphosphate  and 
phosphatidylinositol  3,4,5‐triposphate  5‐phosphatase.  Proc  Natl 
Acad Sci USA. 1996;93:1689‐1693.  
39.  Lioubin  MN,  Algate  PA,  Tsai  S,  Carlberg  K,  Aebersold  A, 
Rohrschneider  LR.  p150Ship,  a signal  transduction molecule  with 
inositol  polyphosphate‐5‐phosphatase  activity.  Genes  &  Devel. 
1996;10:1084‐1095.  
40.  Muraille E, Pesesse X, Kuntz C, Erneux  C. Distribution of the 
src‐homology‐2‐domain‐containing  inositol  5‐phosphatase  SHIP‐2 
in  both  non‐haemopoietic  and  haemopoietic  cells  and  possible 
involvement  in  SHIP‐2  in  negative  signaling  of  B‐cells.  Biochem  J. 
1999;342:697‐705.  
41.  Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, 
Moodie  S,  Stokoe  D.  5’phospholipid  phosphatase  SHIP‐2  causes 
protein kinase B  inactivation  and  cell  cycle  arrest  in  glioblastoma 
cells.  Mol Cell Biol. 2000;20:6860‐6871.  
42.  Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in 
hamartoma  syndromes:  therapeutic  prospects.  Cell  Cycle. 
2009;8:403‐413.  
43.  Vazquez‐Martin  A,  Oliveras‐Ferraros  C,  Lopez‐Bonet  E, 
Menendez JA. AMPK: Evidence for an energy‐sensing cytokinetic 
tumor suppressor. Cell Cycle. 2009;8:3679‐3683.  
44.  Tamburini  J,  Green  AS,  Chapuis  N,  Bardet  V,  Lacombe  C, 
Mayeux  P,  Bouscary  D.  Targeting  translation  in  acute  myeloid 
leukemia: a new paradigm for therapy? Cell Cycle. 2009;8:3893‐
3899.  
45.  Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation 
of  mTORC1  by  Rheb  G‐protein  in  vitro  involves  enhanced 
recruitment  of 
J  Biol  Chem. 
2009;284:12783‐12791.  
46.  Carracedo  A,  Ma  L,  Teruya‐Feldstein  J,  Rojo  F,  Salmena  L, 
Alimonti  A,  Egia  A,  Sasaki  AT,  Thomas  G,  Kozma  SC,  Papa  A, 

substrate  protein. 

its 

  
www.impactaging.com 

 

 

 

           215                                          AGING, March 2011, Vol.3 No.3

Nardella C, et al. Inhibition of mTORC1 leads to MAPK pathway 
activation  through a  PI3K‐dependent  feedback  loop  in  human  
cancer. J Clin Invest. 2008;118:3065‐3074.  
47.  Hresko  RC,  Mueckler  M.  mTOR.RICTOR  is  the  Ser473  kinase 
for  Akt/protein  kinase  B  in  3T3‐L1  adipocytes.  J  Biol  Chem. 
2005;280:40406‐40416.  
48.  Gonzalez E, McGraw TE. The Akt kinases: isoform specificity 
in metabolism and cancer. Cell Cycle. 2009;8:2502‐2508.  
49.  Narasimhan  SD,  Mukhopadhyay  A,  Tissenbaum  HA. 
InAKTivation  of  insulin/IGF‐1  signaling  by  dephosphorylation. 
Cell Cycle. 2009;8:3878‐3884.  
50.  Larrea  MD,  Wander  SA,  Slingerland  JM.  p27  as  Jekyll  and 
Hyde:  regulation  of  cell  cycle  and  cell  motility.  Cell  Cycle. 
2009;8:3455‐3461.  
51.  Mobasheri  A,  Richardson  S,  Mobasheri  R,  Shakibaei  M, 
Hoyland  JA.  Hypoxia  inducible  factor‐1  and  facilitative  glucose 
transporters GLUT1 and GLUT3: putative molecular components of 
the  oxygen  and  glucose  sensing  apparatus 
in  articular 
chondrocytes. Histol Histopathol. 2005;20:1327‐1338.  
52.  Eitel  JA,  Bijangi‐Vishehsaraei  K,  Saadatzadeh  MR,  Bhavsar 
JR, Murphy MP, Pollok KE, Mayo LD. PTEN and p53 are required 
for hypoxia induced expression of maspin in glioblastoma cells. 
Cell Cycle. 2009;8:896‐901.  
53.  Domina  AM,  Vrana  JA,  Gregory  MA,  Hann  SR,  Craig  RW. 
MCL1 is phosphorylated in the PEST region and stabilized upon ERK 
activation  in  viable  cells,  and  at  additional  sites  with  cytotoxic 
okadaic acid or taxol. Oncogene. 2004;23:5301‐5315.  
54.  Wang  JM,  Chao  JR,  Chen  W,  Kuo  ML,  Yen  JJ,  Yang‐Yen  HF. 
The  antiapoptotic  gene  Mcl‐1 
the 
phosphatidylinositol  3‐kinase/Akt  signaling  pathway  through  a 
transcription  factor  complex  containing  CREB.  Mol  Cell  Biol. 
1999;19:6195‐6206.  
55.  Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer 
LM, Heasley LE, Reusch JE. Akt/protein kinase B up‐regulates Bcl‐2 
expression through cAMP‐response element‐binding protein. J Biol 
Chem. 2000;275:10761‐10766.  
56.  Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton 
J,  Sonenberg  N,  Blenis  J.  RAS/ERK  signaling  promotes  site‐
specific  ribosomal  protein  S6  phosphorylation  via  RSK  and 
stimulates 
Chem. 
2007;282:14056‐14064.  
57.  Shahbazian  D,  Roux  PP,  Mieulet  V,  Cohen  MS,  Raught  B, 
Tauton  J,  Hershey  JW,  Blenis  J,  Pende  M,  Sonenberg  N.  The 
mTOR/PI3K and MAPK pathways converge on eIF4B to control its 
phosphorylation and activity. EMBO J. 2006;25:2781‐2791.  
58.  Datta  SR,  Dudek,  H,  Tao  X,   Masters   S,  Fu  H,  Gotoh  Y, 
Greenberg  ME.  Akt  phosphorylation  of  BAD  couples  survival 
signals to the cell‐intrinsic death machinery. Cell. 1997; 91:231‐241.  
59.  Fletcher JI, Huang DC. Controlling the cell death mediators Bax 
and Bak: puzzles and conundrums. Cell Cycle. 2008;7:39‐44.  
60.  Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer 
PJ.  Expression  of  the  pro‐apoptotic  Bcl‐2  family  member  Bim  is 
regulated by the forkhead transcription factor FKHR‐L1. Curr Biol. 
2000;10:1201‐1204.  
61.  Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is 
phosphorylated  by  Akt  and  regulates  BimEL  apoptotic  function.  J 
Biol Chem. 2006; 281:813‐823.  
62.  Steelman  LS,  Abrams  SL,  Whelan  J,  Bertrand  FE,  Ludwig  DE, 
Basecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati 

is  upregulated  by 

Biol 

Cap‐dependent 

translation. 

J 

A, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR 
and JAK/STAT pathways to leukemia. Leukemia. 2008;22:686‐707.  
63.  De  La  O  JP,  Murtaugh  LC.  Notch  and  Kras  in  pancreatic 
cancer:  at  the  crossroads  of  mutation,  differentiation  and 
signaling.  Cell Cycle. 2009;8:1860‐1864.  
64.  Liu  Y,  Dean  DC.  Tumor  initiation  via  loss  of  cell  contact 
inhibition  versus  Ras  mutation:  do  all  roads  lead  to  EMT?  Cell 
Cycle. 2010;9:897‐900.  
65.  Goel  VK,  Lazar  AJ,  Warneke  CL,   Redston   MS,  Haluska  FG. 
Examination  of  mutations  in  BRaf,  NRas  and  PTEN  in  primary 
cutaneous melanoma. J Inv Dermatology. 2006;126:154‐160.  
66.  Dahl C, Guidberg P. The genome and epigenome of malignant 
melanoma. APMIS. 2007;115:1161‐1176.  
67.  Bacher  U,  Haferlach  T,  Schoch  C,  Kern  W,  Schnittger  S. 
Implications of NRAS mutations in AML: a study of 2502 patients. 
Blood. 2006;107:3847‐3853.  
68.  Wang  S,  Koromilas  AE.  Stat1  is  an  inhibitor  of  Ras‐MAPK 
signaling and  Rho small GTPase expression with implications  in 
the transcriptional signature of Ras transformed cells. Cell Cycle. 
2009;8:2070‐2079.  
69.  Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, 
Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, et 
al.  Prognostic  implication  of  FLT3  and  N‐RAS  gene  mutations  in 
acute myeloid leukemia. Blood. 1999;93:3074‐3080.  
70.  Tannapfel A, Sommerer F, Benicke  M, Katalinic  A,  Uhlmann 
D,  Witzigmann  H,  Hauss  J,  Wittekind  C.  Mutations  of  the  BRAF 
gene  in  cholangiocarcinoma  but  not  in  hepatocellular  carcinoma. 
Gut. 2003;52:706‐712.  
71.  Shan  W,  Liu  J.  Epithelial  ovarian  cancer:  focus  on  genetics 
and animal models. Cell Cycle. 2009;8:731‐735.  
72.  Davies  H,  Bignell  GR,  Cox  C,  Stephens  P,  Edkins  S,  Clegg  S, 
Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks 
E,  et  al.  Mutations  of  the  BRAF  gene  in  human  cancer.  Nature. 
2002;417:949‐954.  
73.  Libra L, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua 
V,  Proietti  L,  Bruni  B,  Stivala  F,  Mazzarino  MC,  Travali  S, 
McCubrey  JA.  al.  Analysis  of  BRAF  mutation  in  primary  and 
metastatic melanoma. Cell Cycle. 2005;4:1382‐1384.  
74.  Fransén K, Klintenäs M, Osterström A, Dimberg  J,  Monstein 
HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF‐1 
genes 
in  human  colorectal  adenocarcinomas.  Carcinogenesis. 
2004;25:527‐533.  
75.  Wan  PT,  Garnett  MJ,  Roe  SM,  Lee  S,  Niculescu‐Duvaz  D, 
Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais 
R;  Cancer  Genome  Project. Mechanism of activation of the RAF‐
ERK  signaling  pathway  by  oncogenic  mutations  of  B‐RAF.  Cell. 
2004;116:855‐867.  
76.  Buscà  R,  Abbe  P,  Mantoux  F,  Aberdam  E,  Peyssonnaux  C, 
Eychène  A,  Ortonne  JP,  Ballotti  R.  Ras  mediates  the  cAMP‐
dependent  activation  of  extracellular  signal‐regulated  kinases 
(ERKs) in melanocytes. EMBO J. 2000;19:2900‐2910.  
77.  Rushworth LK, Hindley AD, O'Neill E, Kolch W. Regulation and 
role  of  Raf‐1/B‐Raf  heterodimerization.  Mol  Cell  Biol. 
2006;26:2262‐2272.  
78.  Garnett  MJ,  Rana S,  Paterson  H, Barford  D,  Marais  R.  Wild‐
through  distinct 
type  and  mutant  B‐RAF  activate  C‐RAF 
mechanisms  involving  heterodimerization.  Mol  Cell.  2005;20:963‐
969.  
79.  Zaravinos A,  Kanellou P,  Baritaki S,  Bonavida B,  Spandidos 

  
www.impactaging.com 

 

 

 

           216                                          AGING, March 2011, Vol.3 No.3

DA.  BRAF  and  RKIP  are  significantly  decreased  in  cutaneous 
squamous cell carcinoma. Cell Cycle. 2009;8:1402‐1408.  
80.  Zebisch   A,   Staber   PB,   Delavar   A,   Bodner   C,   Hiden   K,  
Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger 
W, Windpassinger C, Schimek MG, et al. Two transforming C‐RAF 
germ‐line  mutations  identified  in  patients  with  therapy‐related 
acute myeloid leukemia. Cancer Res. 2006;166:3401‐3408.  
81.  Zebisch A, Haller M, Hiden K, Goebel T, Hoefler G, Troppmair 
J, Sill H.  Loss of Raf kinase inhibitor protein is a somatic event in 
the pathogenesis of therapy‐related acute myeloid leukemias with 
c‐RAF germline mutations. Leukemia. 2009;23:1049‐1053.  
82.  Rodriguez‐Viciana  P,  Tetsu  O,  Tidyman  WE,  Estep  AL, 
Conger  BA,  Cruz  MS,  McCormick  F,  Rauen  KA.  Germline 
mutations  in  genes  within  the  MAPK  pathway  cause  cardio‐
facio‐cutaneous syndrome. Science. 2006:311:1287‐1290.  
83.  Nystrom A‐M, Ekvall S, Berglund E, Bjorkqvist M, Braaten G, 
Duchen  K,  Enell  H  Holmberg  E,  Holmund  U,  Olsson‐Engman  M 
Anneren G, Bondeson M‐L. Noonan and cardio‐facio‐cutaneous 
syndromes: two clinically and genetically overlapping disorders. 
J Med Genet. 2008;45:500‐506.  
84.  Murugan  AK,  Dong  J,  Xie  J,  Xing  M.   MEK1  mutations,  but 
not ERK2 mutations, occur in melanomas and colon carcinomas, 
but none in thyroid carcinomas. Cell Cycle. 2009;8:2122‐2124.  
85.  El‐Serag  HB,  Rudolph  KL.  Hepatocellular  carcinoma: 
epidemiology  and  molecular  carcinogenesis.  Gastroenterology. 
2007;132:2557‐2576.  
86.  Montalto  G,  Cervello  M,  Giannitrapani  L,  Dantona  F, 
Terranova  A,  Castagnetta  LA.  Epidemiology,  risk  factors,  and 
natural  history  of  hepatocellular  carcinoma.  Ann  N  Y  Acad  Sci. 
2002;963:13‐20.  
87.  Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over‐
expression of the mitogen‐activated protein kinase (MAPK) kinase 
(MEK)–MAPK 
in  tumor 
progression and apoptosis. BMC Gastroenterol. 2003;3:19.  
88.  Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, 
Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi 
protein 
of  mitogen‐activated 
N, 
kinases/extracellular 
in 
human 
hepatocellular carcinoma. Hepatology. 1998;27:951‐958.  
89.  Tanimura  S,  Chatani  Y,    Hoshino  R,  Sato  M,  Watanabe  S, 
Kataoka  T,  Nakamura  T,  Kohno  M.  Activation  of the 41/43  kDa 
mitogen‐activated protein kinase signaling pathway is required for 
hepatocyte  growth  factor‐induced  cell  scattering.  Oncogene. 
1998;17:57‐65.  
90.  Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura 
M,  Matsuda  Y,  Nomoto  M,  Aoyagi  Y.  Overexpression  of 
extracellular  signal–regulated  protein  kinase  and  its  correlation 
with  proliferation  in  human  hepatocellular  carcinoma.  Liver  Int. 
2004;24:432‐436.  
91.  Calvisi  DF,  Ladu  S,  Gorden  A,  Farina  M,  Conner  EA,  Lee  JS, 
Factor  VM,  Thorgeirsson  SS.  Ubiquitous  activation  of  Ras  and 
Jak/Stat 
pathways 
human  HCC.  Gastroenterology. 
2006;130:1117–1128.  
92.  Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff 
P,  Lo  TL,  Leung  HY,  So  SK,  Guy  GR.  Sprouty  2,  an  inhibitor  of 
mitogen‐activated  protein  kinase  signaling,  is  down‐regulated  in 
hepatocellular carcinoma. Cancer Res. 2006;66:2048–2058.  
93.  Yoshida  T,  Hisamoto  T,  Akiba  J,  Koga  H,  Nakamura  K, 
Tokunaga  Y,  Hanada  S,  Kumemura  H,  Maeyama  M,  Harada  M, 
Ogata  H,  Yano  H,  et  al.  Spreds,  inhibitors  of  the  Ras/ERK  signal 

in  hepatocellular  carcinoma: 

signal‐regulated 

Activation 

its  role 

in 

et 

al. 

kinases 

factor 

carcinoma. 

for  hepatocellular 

transduction, are dysregulated in human hepatocellular carcinoma 
and  linked  to  the  malignant  phenotype  of  tumors.  Oncogene. 
2006;25:6056–6066.  
94.  Lee  HC,  Tian  B,  Sedivy  JM,  Wands  JR,  Kim  M.    Loss  of  Raf 
kinase  inhibitor  protein promotes  cell  proliferation  and  migration 
of human hepatoma cells. Gastroenterology. 2006;131:1208‐1217. 
95.  Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip‐
Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt‐Leopold JS. 
The  effects  of  a  novel  MEK  inhibitor  PD184161  on  MEK‐ERK 
signaling and growth in human liver cancer. Neoplasia. 2006;8:1‐8.  
96.  Galle PR. Sorafenib in advanced hepatocellular carcinoma.‐we 
have won a battle but not the war. J Hepatology. 2008;49:871‐873.  
97.  Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, 
Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a 
Liver  Transpl. 
risk 
2004;10:S69–S73.  
98.  Saxena  NK,  Sharma  D,  Ding  X,  Lin  S,  Marra  F,  Merlin  D, 
Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and 
ERK signaling is involved in leptin‐mediated promotion of invasion 
and  migration  of  hepatocellular  carcinoma  cells.  Cancer  Res. 
2007;67:2497‐2507. 
99.  Schmitz   KJ,   Wohlschlaeger  J,  Lang  H,  Sotiropoulos  GC, 
Malago  M,  Steveling  K,  Reis  H,  Cicinnati  VR,  Schmid  KW,  Baba 
HA. Activation of the ERK and AKT signalling pathway predicts poor 
prognosis in hepatocellular carcinoma and ERK activation in cancer 
tissue  is  associated  with  hepatitis  C  virus  infection.  J  Hepatol. 
2008;48:83‐90.  
100. Benn J, Schneider, RJ. Hepatitis B virus HBx protein activates 
Ras‐GTP complex formation and establishes a Ras, Raf, MAP kinase 
signaling cascade. Proc Natl Acad Sci USA. 1994;91:10350–10354.  
101. Yun  C,  Cho  H,  Kim  SJ,  Lee  JH,  Park  SY,  Chan  GK,  Cho  H. 
Mitotic  aberration  coupled  with  centrosome  amplification 
is 
induced  by  hepatitis  B  virus  X  oncoprotein  via  the  Ras‐mitogen‐
activated  protein/extracellular  signal‐regulated  kinase‐mitogen‐
activated protein pathway. Mol Cancer Res. 2004;2:159–169.  
102. Chung  TW,  Lee  YC,  Kim  CH.  Hepatitis  B  viral  HBx  induces 
matrix metalloproteinase‐9 gene expression through activation of 
ERK  and  PI‐3K/AKT  pathways:  involvement  of  invasive  potential. 
FASEB J. 2004;18:1123‐1125.  
103. Niepmann M.  Activation of hepatitis C virus translation by 
a liver‐specific microRNA. Cell Cycle. 2009;8:1473‐1477, 2009.  
104. Shor  B,  Gibbons  JJ,  Abraham  RT,  Yu  K.   Targeting   mTOR 
globally 
in  cancer:  thinking  beyond  rapamycin.  Cell  Cycle. 
2009;8:3831‐3837.  
105. Wang X, Meng X, Sun X, Liu M, Gao S, Zhao J, Pei F, Yu H. 
Wnt/beta‐catenin signaling pathway may regulate cell cycle and 
expression  of  cyclin  A  and  cyclin  E  protein  in  hepatocellular 
carcinoma cells. Cell Cycle. 2009;8:1567‐1570.  
106. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan 
H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, et 
al.  High  frequency  of  mutations  of  the  PIK3CA  gene  in  human 
cancers. Science. 2004;304:554.  
107. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into 
the  oncogenic  effects  of  PIK3CA  mutations  from  the  structure  of 
p110alpha/p85alpha. Cell Cycle. 2008;7:1151‐1156.  
108. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim 
SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in 
breast  carcinomas  and  hepatocellular  carcinomas.  Oncogene. 
2005;24:1477‐1480.  
109. Shatyesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, 

  
www.impactaging.com 

 

 

 

           217                                          AGING, March 2011, Vol.3 No.3

Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an 
oncogene in ovarian cancer. Nat Genet. 1999;21:99‐102.  
110. Ligresti  G,  Militello  L,  Steelman  LS,  Cavallaro  A,  Basile  F, 
Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in 
human solid tumors. Cell Cycle. 2009:8:1352‐1358.  
111. Calvisi  DF,  Ladu  S,  Gorden  A,  Farina  M,  Lee  JS,  Conner  EA, 
Schroeder  I,  Factor  VM,  Thorgeirsson  SS.  Mechanistic  and 
prognostic  significance  of  aberrant  methylation  in  the  molecular 
pathogenesis  of  human  hepatocellular  carcinoma.  J  Clin  Invest. 
2007;117:2713‐2722.  
112. Steelman  LS,  Bertrand  FE,  McCubrey  JA.  The  complexity  of 
PTEN:  mutation,  marker  and  potential  target  for  therapeutic 
intervention. Expert Opinion Ther Targets. 2004;8:537‐550.  
113. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. 
Mutation  analysis  of  the  putative  tumor  suppressor  gene 
PTEN/MMAC1 
in  primary  breast  carcinomas.  Cancer  Res. 
1997;57:3657‐3659.  
114. Singh  B,  Ittmann  MM,  Krolewski  JJ.  Sporadic  breast  cancers 
exhibit  loss  of  heterozygosity  on  chromosome  segment  10q23 
close  to  the  Cowden  disease  locus.  Genes  Chromosome  Can  . 
1998;21:166‐171.  
115. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya‐Feldstein J, 
Yang  H,  Pavletich  NP,  Carver  BS,  Cordon‐Cardo  C,  Erdjument‐
Bromage H, Tempst P, Chi SG, et al. Ubiquitination regulates PTEN 
nuclear import and tumor suppression. Cell. 2007;128:141‐156.  
116. Kappes  H,  Goemann  C,  Bamberger  AM,  Löning  T,  Milde‐
Langosch  K.  PTEN  expression  in  breast  and  endometrial  cancer: 
correlation  with  steroid  hormone  receptor  status.  Pathobiology. 
2001;69:136‐142.  
117. Suzuki  A,  Nakano  T,  Mak  TW,  Sasaki  T.  Portrait  of  PTEN: 
messages from mutant mice. Cancer Sci. 2008;99:209‐213.  
118. Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, 
Lee  PH,  Peacocke  M,  Santella  RM,  Tsou  HC.  PTEN/MMAC1 
mutations in hepatocellular carcinomas. Oncogene. 1999;18:3181‐
3185.  
119. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, Perng LI, 
Wang  JC,  Tsai  M,  Chang  CP.  Mutation  analysis  of  the  putative 
tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. 
Cancer Invest. 2000;18:123‐129.  
120. Kawamura  N,  Nagai  H,  Bando  K,  Koyama  M,  Matsumoto  S, 
Tajiri T, Onda M, Fujimoto J, Ueki T, Konishi N, Shiba T, Emi M. 
PTEN/MMAC1  mutations  in  hepatocellular  carcinomas:  somatic 
inactivation  of  both  alleles 
in  tumors.  Jpn  J  Cancer  Res. 
1999;90:413‐418.  
121. Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, Sakon 
M, Nishisho I, Monden M. PTEN/MMAC1 mutation and frequent 
loss of heterozygosity identified in chromosome 10q in a subset of 
hepatocellular carcinomas. Jpn J Cancer Res. 2000;91:287‐292.  
122. Wang  L,  Wang  WL,  Zhang  Y,  Guo  SP,  Zhang  J,  Li  QL. 
Epigenetic  and  genetic  alterations  of  PTEN  in  hepatocellular 
carcinoma. Hepatol Res. 2007;37:389‐396.  
123. Rahman  MA,  Kyriazanos  ID,  Ono  T,  Yamanoi  A,  Kohno  H, 
Tsuchiya  M,  Nagasue  N.  Impact  of  PTEN  expression  on  the 
outcome  of  hepatitis  C  virus‐positive  cirrhotic  hepatocellular 
carcinoma patients: possible relationship with COX II and inducible 
nitric oxide synthase. Int J Cancer. 2002;100:152‐157.  
124. Hu  TH,  Wang  CC,  Huang  CC,  Chen  CL,  Hung  CH,  Chen  CH, 
Wang  JH,  Lu  SN,  Lee  CM,  Changchien  CS,  Tai  MH.  Down‐
regulation of tumor suppressor gene PTEN, overexpression of p53, 
plus  high  proliferating  cell  nuclear  antigen  index  predict  poor 

in 

patient outcome of hepatocellular carcinoma after resection. Oncol 
Rep. 2007;18:1417‐1426.  
125. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B Virus X protein 
modulates the expression of PTEN by inhibiting the function of p53, 
a transcriptional activator in liver cells. Cancer Res. 2003;63:3453‐
3458.  
126. Kang‐Park S, Im JH, Lee JH, Lee YI. PTEN modulates hepatitis B 
virus‐X protein induced survival signaling in Chang liver cells. Virus 
Res. 2006;122:53‐60.  
127. Dhomen  N,  Reis‐Filho  JS,  da  Rocha  Dias  S,  Hayward  R, 
Savage  K,  Delmas  V,  Larue  L,  Pritchard  C,  Marais  R.  Oncogenic 
Braf  induces  melanocyte  senescence  and  melanoma  in  mice. 
Cancer Cell. 2009;15:294‐303.  
128. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, 
Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. 
Braf(V600E)  cooperates  with  PTEN  loss  to  induce  metastatic 
melanoma. Nat Genet. 2009;41:544‐552.  
129. Butler MP, Wang SI, Chaganti RS, Parsons R, Dalla‐Favera R. 
Analysis  of  PTEN  mutations  and  deletions  in  B‐cell  non‐Hodgkin's 
lymphomas. Genes Chromosomes Cancer. 1999;24:322‐327.  
130. Sakai  A,  Thieblemont  C,  Wellmann  A,  Jaffe  ES,  Raffeld  M. 
PTEN  gene  alterations 
lymphoid  neoplasms.  Blood. 
1998;92:3410‐3415.  
131. Uddin  S,  Hussain  A,  Al  Hussein  K,  Platanias  LC,  Bhatia  KG. 
Inhibition  of  phosphatidylinositol  3'‐kinase  induces  preferentially 
killing  of  PTEN‐null  T  leukemias  through  AKT  pathway.  Biochem 
Biophys Res Commun. 2004;320:932‐938.  
132. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, 
Caparros  E,  Buteau  J,  Brown  K,  Perkins  SL,  Bhagat  G,  Agarwal 
AM, et al. Mutational loss of PTEN induces resistance to NOTCH1 
inhibition in T‐cell leukemia. Nat Med. 2007;13:1203‐1210.  
133. Palomero  T,  Dominguez  M,  Ferrando  AA.  The  role  of  the 
PTEN/AKT  Pathway  in  NOTCH1‐induced  leukemia.  Cell  Cycle. 
2008;7:965‐970. 
134. Garcia JM, Silva  J,  Pena C, Garcia  V,  Rodríguez  R,  Cruz  MA, 
Cantos B, Provencio M, España P, Bonilla F. Promoter methylation 
of the PTEN gene is a common molecular change in breast cancer. 
Genes Chromosomes Cancer. 2004;41:117‐124.  
135. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori 
M.  Reduced  expression  of  PTEN  protein  and  its  prognostic 
implications in invasive ductal carcinoma of the breast. Oncology.  
2005;68:398‐404. 
136. Yang  H,  Kong  W,  Zhao  JJ,  O'Donnell  JD,  Wang  J.  MicroRNA 
expression profiling in human ovarian cancer: miR‐274 induces cell 
survival  and  cisplatin  resistance  by  targeting  PTEN.  Cancer  Res. 
2008;68:425‐433.  
137. Luo  JM,  Yoshida  H,  Komura  S,  Ohishi  N,  Pan  L,  Shigeno  K, 
Hanamura  I,  Miura  K,  Iida  S,  Ueda  R,  Naoe  T,  Akao  Y,  et  al. 
Possible  dominant‐negative  mutation  of  the  SHIP  gene  in  acute 
myeloid leukemia. Leukemia. 2003;17:1‐8.  
138. Metzner A, Horstmann MA, Fehse B, Ortmeyer G, Niemeyer 
CM,  Stocking  C,    Mayr  GW,  Jücker  M.  Gene  transfer  of  SHIP‐1 
inhibits  proliferation  of  juvenile  myelomonocytic  leukemia  cells 
carrying KRAS2 or PTPN11 mutations. Gene Ther. 2007;14:699‐703.  
139. Cheng  JQ,  Godwin  AK,  Bellacosa  A,  Taguchi  T,  Franke  TF, 
Hamilton  TC,  Tsichlis  PN,  Testa  JR.  AKT2,  a  putative  oncogene 
encoding  a  member  of  a  subfamily  of  protein‐serine/threonine 
kinases, is amplified in human ovarian carcinomas. Proc Natl Acad 
Sci USA. 1992;89:9267‐9271.   
140. Carpten  JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins 

  
www.impactaging.com 

 

 

 

           218                                          AGING, March 2011, Vol.3 No.3

CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin 
A,  et  al.  A  transforming  mutation  in  the  pleckstrin  homology 
domain of AKT1 in cancer. Nature. 2007;448:439‐444.  
141. Stemke‐Hale  K,  Gonzalez‐Angelo  M,  Lhuch  A  Neve  RM,  Kuo 
WL,  Davies  M,  Carey  M,  Hu  Z,  Guan  Y,  Sahin  A,  Symmans  WF, 
Pusztai L, et al. An integrative genomic and proteomic analysis of 
PIK3CA,  PTEN  and  Akt  mutations  in  breast  cancer.  Cancer  Res. 
2008;68:6084‐6091.  
142. Bellacosa  A,  DeFeo  D,  Godwin  AK,  Bell  DW,  Cheng  JQ, 
Altomare  DA,  Wan  M,  Dubeau  L,  Scambia  G,  Masciullo  V, 
Ferrandina  G,  Benedetti  Panici  P,  et  al.  Molecular  alterations  of 
the Akt oncogene in breast cancer. Int J Cancer. 1995;64:280‐285.  
143. Davies MA, Stemke‐Hale K, Tellez C, Calderone TL, Deng W, 
Prieto  VG,  Lazar  AJ,  Gershenwald  JE,  Mills  GB.   A   novel  Akt3 
mutation  in  melanoma  tumours  and  cell  lines.  Brit  J  Cancer. 
2008;99:1265‐1268. 
144. Greenman  C,  Stephens  P,  Smith  R,  Dalgliesh  GL,  Hunter  C, 
Bignell  G,  Davies  H,  Teague  J,  Butler  A,  Stevens  C,  Edkins  S, 
O'Meara  S,  et  al.  Patterns  of  somatic  mutation  in  human  cancer 
genomes.  Nature. 2007;446:153‐158.  
145. Karst AM, Dai DL, Cheng JQ, Li  G.  Role of p53 up‐regulated 
modulator of apoptosis and phosphorylated Akt in melanoma cell 
growth, apoptosis and patient survival.  Cancer Res. 2006;66:9221‐
9226.  
146. Slipicevic  A,  Holm  R,  Nguyen  MTP,  Bøhler  PJ,  Davidson  B, 
Flørenes VA.  Expression  of activated Akt and PTEN in  malignant 
melanomas:  Relationship with  clinical  outcome.  Am  J  Clin  Pathol. 
2005;124:528‐536.  
147. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein‐Szanto A, Wang 
H, Unger M, Testa JR. Frequent activation of AKT in non‐small cell 
lung 
lesions.  
Carcinogenesis. 2004;25:2053‐2059. 
148. Shah  A,  Swain  WA,  Richardson  D,  Edwards  J,  Stewart  DJ, 
Richardson  CM,  Swinson  DE,  Patel  D,  Jones  JL,  O'Byrne  KJ. 
Phospho‐Akt expression is associated with a favorable outcome in 
non‐small cell lung cancer. Clin Cancer Res. 2005;11:2930‐2936.  
149. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa 
JR. AKT activation up‐regulates insulin‐like growth factor I receptor 
expression and promotes invasiveness of human pancreatic cancer 
cells. Cancer Res. 2001;61:589‐593. 
150. St‐Germain ME, Gagnon V, Parent S, Asselin E. Regulation of 
COX‐2  protein  expression  by  Akt  in  endometrial  cancer  cells  is 
mediated through NF‐B/IB pathway.  Mol Cancer. 2004;3:7.  
151. Chow 
S,  Minden  MD,  Hedley  DW.  Constitutive 
phosphorylation  of  the  S6  ribosomal  protein  via  mTOR  and  ERK 
signaling  in  the  peripheral  blasts  of  acute  leukemia  patients.  Exp 
Hematol. 2006;34:1183‐1191.  
152.  Grandage VL, Gale RE, Linch DC, Khwaja A. PI3‐kinase/Akt is 
constitutively active in primary acute myeloid leukaemia cells and 
regulates survival and chemoresistance via NF‐kappaB, Mapkinase 
and p53 pathways. Leukemia. 2005;19:586‐594.  
153. Ricciardi  MR,  McQueen  T,  Chism  D,  Milella  M,  Estey  E, 
Kaldjian  E,  Sebolt‐Leopold  J,  Konopleva  M,  Andreeff  M. 
Quantitative single cell determination of ERK phosphorylation and 
regulation  in  relapsed  and  refractory  primary  acute  myeloid 
leukemia. Leukemia. 2005;19:1543‐1549.  
154. McCubrey  JA,  Milella  M,  Tafuri  A,  Martelli  AM,  Lunghi  P, 
Bonati  A,  Bonati  A,  Cervello  M,  Lee  JT,  Steelman  LS.  Targeting 
the Raf/MEK/ERK pathway with small molecule inhibitors.  
Current Opinion Investigational Drugs. 2008;9:614‐630.  

preneoplastic 

carcinomas 

bronchial 

and 

FM, 

Ross 

Cell 

Platt 

RL,  Hurst 

155. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo 
S,  Ove  R,  Milella  M,  Tafuri  A,  Lunghi  P,  Bonati  A,  Stivala  F, 
Nicoletti  F,  et  al.  Emerging  MEK  Inhibitors.  Exp  Opin  Emerging 
Drugs. 2010; 15:203‐223.  
156. Hu  TH,  Huang  CC,  Lin  PR,  Chang  HW,  Ger  LP,  Lin  YW, 
Changchien CS, Lee CM, Tai MH. Expression and prognostic role of 
tumor  suppressor  gene  PTEN/MMAC1/TEP1 
in  hepatocellular 
carcinoma. Cancer. 2003;97:1929–1940.  
157. Lee  YI,  Kang‐Park  S,  Do  SI,  Lee  YI.  The  hepatitis  B  virus‐X 
protein  activates  a  phosphatidylinositol  3‐kinase‐dependent 
survival signaling cascade. J Biol Chem. 2001;276:16969‐16977.  
158. Mannová P, Beretta L. Activation of the N‐Ras‐PI3K‐Akt‐mTOR 
pathway  by  hepatitis  C  virus:  control  of  cell  survival  and  viral 
replication. J Virol. 2005;79:8742‐8749.  
159. Knowles  MA, 
CD. 
Phosphatidylinositol 3‐kinase (PI3K) pathway activation in bladder 
cancer. Cancer Metastasis Rev. 2009;28:305‐316.  
160. Graff  JR,  Zimmer  SG.  Translational  control  and  metastatic 
progression:  enhanced  activity  of  the  mRNA  cap‐binding  protein 
eIF‐4E  selectively  enhances  translation  of  metastasis‐related 
mRNAs. Clin Exp Metastasis. 2003;20:265‐273.  
161. Zimmer SG, DeBenedetti A, Graff JR. Translational control of 
malignancy:  the  mRNA  cap‐binding  protein,  eIF‐4E,  as  a  central 
regulator  of  tumor  formation,  growth,  invasion  and  metastasis. 
Anticancer Res. 2000;20:1343‐1351.  
162. Galmozzi E, Casalini P, Iorio MV, Casati B, Olgiati C, Menard S. 
HER2  signaling  enhances  5'UTR‐mediated  translation  of  c‐Myc 
mRNA. J Cell Physiol. 2004;200:82‐88.  
163. Podar  K.  Anderson  KC.    A  therapeutic  role  for  targeting  c‐
Myc/Hif‐1‐dependent 
Cycle. 
2010;9:1722‐1728.  
164. Gera  JF,  Mellinghoff  IK,  Shi  Y,  Rettig  MB,  Tran  C,  Hsu  JH, 
Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to 
mammalian  target  of  rapamycin  (mTOR)  inhibitors  by  regulating 
cyclin D1 and c‐myc expression. J Biol Chem. 2004;279:2737‐2746.  
165. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. 
Integrin  (alpha  6  beta  4)  regulation  of  eIF‐4E  activity  and  VEGF 
translation:  a  survival  mechanism  for  carcinoma  cells.  J  Cell  Biol. 
2002;158:165‐174.  
166. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon‐Cardo C. 
Overexpression of cyclin D1 is associated with metastatic prostate 
cancer to bone. Clin Cancer Res. 2000;6:1891‐1895.  
167. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, 
Eeles  RA,  Kirby  RS.  Molecular  markers  for  predicting  prostate 
cancer stage and survival. BJU Int. 2000;6:869‐878.  
168. Gallant  P,  Steiger  D.  Myc's  secret  life  without  Max.  Cell 
Cycle. 2009;8:3848‐3853.  
169. Hydbring  P,  Larsson  LG.  Cdk2:  a  key  regulator  of  the 
senescence control function of Myc. Aging. 2010;2:244‐250.  
170. Jin J, Wang GL, Timchenko L, Timchenko NA. GSK3beta and 
aging liver. Aging. 2009;1:582‐585.  
171. Gan  B,  DePinho  RA.  mTORC1 
signaling  governs 
hematopoietic  stem  cell  quiescence.   Cell   Cycle.  2009;8:1003‐
1006.  
172. Lluis  F,  Cosma  MP.   Somatic   cell  reprogramming  control: 
signaling  pathway  modulation  versus  transcription 
factor 
activities. Cell Cycle. 2009;8:1138‐1144.  
173. Wu  GJ,  Sinclair  CS,  Paape  J,  Ingle  JN,  Roche  PC,  James  CD, 
Couch FJ.  17q23  amplifications  in breast cancer involve the PAT1, 
RAD51C, PS6K and SIGma1B genes. Cancer Res. 2000;60:5371‐5375 

pathways. 

signaling 

  
www.impactaging.com 

 

 

 

           219                                          AGING, March 2011, Vol.3 No.3

174. Barlund  M,  Forozan  F,  Kononen  J,  Bubendorf  L,  Chen  Y, 
Bittner  ML,  Torhorst  J,  Haas  P,  Bucher  C,  Sauter  G,  Kallioniemi 
OP,  Kallioniemi  A.  Detecting  activation  of  ribosomal  protein  S6 
kinase  by  complementary  DNA  and  tissue  microarray  analysis.  J 
Natl Cancer Inst. 2000;92:1252‐1259.  
175. Neshat  MS,  Mellinghoff  IK,  Tran  C,  Stiles  B,  Thomas  G, 
Petersen  R,  Frost  P,  Gibbons  JJ,  Wu  H,  Sawyers  CL.  Enhanced 
sensitivity  of  PTEN‐deficient  tumors  to  inhibition  of  FRAP/mTOR. 
Proc Natl Acad Sci USA. 2001;98:10314‐10319.  
176. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, 
Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, et al. 
An  inhibitor  of  mTOR  reduces  neoplasia  and  normalizes  p70/S6 
kinase  activity 
in  PTEN+/‐  mice.  Proc  Natl  Acad  Sci  USA. 
2001;98:10320‐10325. 
177. Wu  C,  Huang 
J.  Phosphatidylinositol  3‐kinase‐AKT‐
mammalian  target  of  rapamycin  pathway 
is  essential  for 
neuroendocrine differentiation of prostate cancer. J Biol Chem. 
2007;282:3571‐3583.  
178. Kinkade CW, Castillo‐Martin M, Puzio‐Kuter A, Yan J, Foster 
TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon‐Cardo C, Abate‐
Shen  C.  Targeting  AKT/mTOR  and  ERK  MAPK  signaling  inhibits 
hormone‐refractory  prostate  cancer  in  a  preclinical  mouse 
model. J Clin Invest. 2008;118:3051‐3064. 
179. Demidenko  ZN,  Korotchkina  LG,  Gudkov  AV,  Blagosklonny 
MV. Paradoxical suppression of cellular senescence by p53. Proc 
Natl Acad Sci USA. 2010;107:9660‐9664.  
180. Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di 
Giandomenico  S,  Koff  A,  Nimer  SD.  The  p53  tumor  suppressor 
protein 
is  a  critical  regulator  of  hematopoietic  stem  cell 
behavior. Cell Cycle. 2009;8:3120‐3124.  
181. Jung‐Hynes  B,  Ahmad  N.  Role  of  p53 
in  the  anti‐
proliferative  effects  of  Sirt1  inhibition  in  prostate  cancer  cells. 
Cell Cycle. 2009;8:1478‐1483.  
182. Yamakuchi M, Lowenstein CJ. MiR‐34, SIRT1 and p53: the feed 
back loop. Cell Cycle. 2009;8:712‐715.  
183. Cheng  Q,  Chen  J.  Mechanism  of  p53  stabilization  by  ATM 
after DNA damage.  Cell Cycle. 2010;9:472‐478.  
184. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element 
and transcriptional repression. Cell Cycle. 2010;9:870‐879.  
185. O'Prey  J,  Crighton  D,  Martin  AG,  Vousden  KH,  Fearnhead 
HO,  Ryan  KM.  p53‐mediated  induction  of  Noxa  and  p53AIP1 
requires NFkappaB.  Cell Cycle. 2010;9:947‐952.  
186. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich 
SJ.YPEL3, a p53‐regulated gene that induces cellular senescence. 
Cancer Res. 2010;70:3566‐575,  
187. Lane DP, Cheok CF, Brown C, Madhumalar A, Ghadessy FJ, 
Verma C. Mdm2 and p53 are highly conserved from placozoans 
to man. Cell Cycle. 2010;9:540‐547.  
188. Ho L, Alman B. Protecting the hedgerow: p53 and hedgehog 
pathway interactions. Cell Cycle. 2010;9:506‐511.  
189. Zawacka‐Pankau J, Kostecka A, Sznarkowska A, Hedstrom E, 
Kawiak A. p73 tumor suppressor protein: a close relative of p53 
not only in structure but also in anti‐cancer approach? Cell Cycle. 
2010;9:720‐728.  
190. Galluzzi  L,  Morselli  E,  Kepp  O,  Maiuri  MC,  Kroemer  G. 
Defective autophagy control by the p53 rheostat in cancer. Cell 
Cycle. 2010;9:250‐255.  
191. Matthew  EM,  Hart  LS,  Astrinidis  A,  Navaraj  A,  Dolloff  NG, 
Dicker DT, Henske EP, El‐Deiry WS. The p53 target Plk2 interacts 
with TSC proteins impacting mTOR signaling, tumor growth and 

conditions.  Cell  Cycle. 

in  the  p53‐mediated 

identifying  optimal  therapeutic  strategy  for 

chemosensitivity  under  hypoxic 
2009;8:4168‐4175.  
192. Mancini  F,  Moretti  F.  Mitochondrial  MDM4  (MDMX):  an 
unpredicted  role 
intrinsic  apoptotic 
pathway. Cell Cycle. 2009;8:3854‐3849.  
193. Kim  DH,  Rho  K,  Kim  S.  A  theoretical  model  for  p53 
dynamics: 
its 
activation and stabilization. Cell Cycle. 2009;8:3707‐3716.  
194. Jain AK, Barton MC. Regulation of p53: TRIM24 enters the 
RING.  Cell Cycle. 2009;8:3668‐3674.  
195. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong ET, 
Basecke J, Troppmair J, Libra N, Nicoletti F, Molton S, McMahon 
M,  Evangelisti  C,  et  al.  Involvement  of  p53  and  Raf/MEK/ERK 
pathways  in  hematopoietic  drug  resistance.  Leukemia.  2008; 
2:2080‐2090.  
196. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong 
EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala 
F,  Libra  M,  et  al.  Roles  of  the  Raf/MEK/ERK  pathway  in  cell 
growth, malignant transformation and drug resistance. Biochim 
Biophys Acta.  2007;1773:1263‐1284.  
197. McCubrey  J,  LaHair  M,  Franklin  RA.  Reactive  oxygen 
species‐induced activation of the MAP kinase signaling pathway. 
Antioxidants & Redox Signaling. 2006;8:1745‐1748.  
198. Franklin  R,  Rodriquez‐Mora  O,  La  Hair  M,  McCubrey  JA. 
Activation of the calcium/calmodulin‐dependent protein kinases 
as  a  consequence  of  oxidative  stress.  Antioxidants  &  Redox 
Signaling. 2006;8:1807‐1817.  
199. Brauer  PM,  Tyner  AL.  RAKing  in  AKT:  a  tumor  suppressor 
function  for  the  intracellular  tyrosine  kinase  FRK.  Cell  Cycle. 
2009;8:2728‐2732.  
200. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling 
activation by ubiquitination. Cell Cycle. 2010;9:487‐497.  
201. Lal  MA,  Bae  D,  Camilli  TC,  Patierno  SR,  Ceryak  S.  AKT1 
mediates bypass of the G1/S checkpoint after genotoxic stress in 
normal human cells.  Cell Cycle. 2009;8:1589‐1602.  
202. Zhang  H.  Skip  the  nucleus,  AKT  drives  Skp2  and  FOXO1  to 
the same place? Cell Cycle. 2010;9:868‐869.  
203. Misaghian  N,  Ligresti  G,  Steelman  LS,   Bertrand   FE, 
Bäsecke  J,  Libra  M,  Nicoletti  F,  Stivala  F,  Milella  M,  Tafuri  A, 
Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic 
stem  cell  –  the  holy  grail  of  leukemia  therapy.  Leukemia. 
2009;23:25‐42.  
204. Yilmaz NH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu 
H,  Morrison  SJ.  PTEN‐dependence  distinguishes  haematopoietic 
stem cells from leukemia‐initating cells. Nature. 2006;441:475‐478.  
205. Zhou  J,  Wulkuhle,  H,  Zhang  H,  Gu  P,  Yang  Y,  Deng  J, 
Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y. Activation of the 
PTEN/mTOR/STAT3  pathway  in  breast  cancer  stem‐like  cells  is 
required  for  viability  and  maintenance.  Proc  Natl  Acad  Sci  USA. 
2007;104:16158‐16163.  
206. Korkaya H, Paulson A, Charafe‐Jauffret E, Ginestier C, Brown 
M,  Dutcher  J,  Clouthier  SG,  Wicha  MS.  Regulation  of  mammary 
stem/progenitor  cells  by  PTEN/Akt/‐catenin  signaling.  PLOS 
Biology. 2009;7: e1000121.  
207. Yim  EK,  Siwko  S,  Lin  SY.  Exploring  Rak  tyrosine  kinase 
function in breast cancer. Cell Cycle. 2009;8:2360‐2364.  
208. Shan  W,  Liu  J.  Epithelial  ovarian  cancer:  focus  on  genetics 
and animal models. Cell Cycle. 2009;8:731‐735.  
209. Saudemont  A,  Colucci  F.  PI3K  signaling  in  lymphocyte 
migration. Cell Cycle. 2009;8:3307‐3310.  

  
www.impactaging.com 

 

 

 

            220                                         AGING, March 2011, Vol.3 No.3

210. Sabisz  M,  Skladonowski  A.  Cancer  stem  cells  and  escape 
from drug‐induced premature senescence in human lung tumor 
cells: implications for drug resistance and in vitro drug screening 
models. Cell Cycle. 2009;8:3208‐3217.  
211. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, 
Stanbridge  EJ,  Lee  EY.  Cancer  stem  cells  contribute  to  cisplatin 
resistance 
in  Brca1/p53‐mediated  mouse  mammary  tumors. 
Cancer Res. 2008;68:3243‐3250.  
212. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. 
The  hypoxic  microenvironment  maintains  glioblastoma  stem 
cells  and  promotes  reprogramming  towards  a  cancer  stem  cell 
phenotype. Cell Cycle. 2009;8:3274‐3284.  
213. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ cancer 
stem cells confer chemoresistance by preferential expression of the 
Akt/PKB survival pathway. Oncogene. 2008;27:1749‐1758.  
214. Li  X,  Lewis  MT,  Huang  J,  Gutierrez  C,  Osborne  CK,  Wu  MF, 
Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen 
J,  et  al.  Intrinsic  resistance  of  tumorigenic  breast  cancer  cells  to 
chemotherapy. J Natl Cancer Inst. 2008;100:672‐679.  
215. McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair 
M,  Ferland  RA,  Steelman  LS.  Targeting  signal  transduction 
pathways  to  eliminate  chemotherapeutic  drug  resistance  and 
cancer stem cells. Advances in Enzyme Regulation. 2010;50:285‐
307.  
216. McCubrey  JA,  Chappell  WH,  Abrams  SL,  Franklin  RA,  Long 
JM,  Sattler  JA,  Kempf  CR,  Laidler  P,  Steelman  LS.  Targeting  the 
cancer initiating cells: the Achilles’ heel of cancer.  Advances in 
Enzyme Regulation. 2011;51: In Press. 
217. Kandouz  M.  Haidara  K.  Zhao  J.  Brisson  ML.  Batist  G.  The 
EphB2  tumor  suppressor  induces  autophagic  cell  death  via 
concomitant  activation  of  the  ERK1/2  and  PI3K  pathways.   Cell  
Cycle. 2010;9:398‐407.  
218. Garinis  GA,  Schumacher  B.  Transcription‐blocking  DNA 
damage in aging and longevity. Cell Cycle. 2009;8:2134‐2135.  
219. Bazarov  AV,  Hines  WC,  Mukhopadhyay  R,  Beliveau  A, 
Meldoyev S, Zaslavsky Y, Yaswen P. Telomerase activation by c‐
Myc  in  human  mammary  epithelial  cells  requires  additional 
genomic changes. Cell Cycle. 2009;8:3373‐3378.  
220. Mele DA, Bista P, Baez DV, Huber BT. Dipeptidyl‐peptidase 
2  is  an  essential  survival  factor  in  the  regulation  of  cell 
quiescence. Cell Cycle. 2009;8:2425‐2434. 
221. Acquaviva C, Chevrier V, Chauvin JP, Fournier G, Birnbaum D, 
Rosnet  O.  The  centasomal  FOP  protein  is  required  for  cell  cycle 
progression and survival. Cell Cycle. 2009;8:1217‐1227.  
222. Jin  J,  Wang  GL,  Salisbury  E,  Timchenko  L,  Timchenko  NA. 
GSK3beta‐cyclin  D3‐CUGBP1‐eIF2  pathway 
in 
myotonic dystrophy. Cell Cycle. 2009;8:2356‐2359.  
223. Gems  D,  Doonan  R.  Antioxidant  defense  and  aging  in  C. 
elegans:  is  the  oxidative  damage  theory  of  aging  wrong?  Cell 
Cycle. 2009;8:1681‐1687.  
224. Perucca  P,  Cazzalini  O,  Madine  M,  Savio  M,  Laskey  RA, 
Vannini  V,  Prosperi  E,  Stivala  LA.  Loss  of  p21  CDKN1A  impairs 
entry  to  quiescence  and  activates  a  DNA  damage  response  in 
normal 
to  quiescence.  Cell  Cycle. 
2009;8:105‐114.  
225. Riffell JL, Zimmerman C, Knong A, McHardy LM, Roberg M. 
Effects  of  chemical  manipulation  of  mitotic  arrest  and  slippage 
on cancer cell survival and proliferation. Cell Cycle. 2009;8:3025‐
3038.  

in  aging  and 

fibroblasts 

induced 

ZN, 

Shtutman  M, 

226. Shan  W,  Liu  J.  Epithelial  ovarian  cancer:  focus  on  genetics 
and animal models. Cell Cycle. 2009;8:731‐735.  
227. Zuin A, Castellano‐Esteve D, Ayte J, Hidalgo E. Living on the 
edge: stress and activation of stress responses promote lifespan 
extension.  Aging. 2010;2:231‐237.  
228. Blagosklonny  MV.  Revisiting  the  antagonistic  pleiotropy 
theory  of  aging:  TOR‐driven  program  and  quasi‐program.   Cell  
Cycle. 2010 Aug 15;9(16):3151‐3156.  
229. Harikumar  KB,  Aggarwal  BB.  Resveratrol:  a  multitargeted 
agent 
for  age‐associated  chronic  diseases.  Cell  Cycle. 
2008;7:1020‐1035.  
230. Demidenko  ZN,  Blagosklonny  MV.  At  concentrations  that 
inhibit  mTOR,  resveratrol  suppresses  cellular  senescence.  Cell 
Cycle. 2009;8:1901‐1904.  
231. Demidenko 
Blagosklonny  MV. 
Pharmacologic  inhibition  of  MEK  and  PI‐3K  converges  on  the 
mTOR/S6  pathway  to  decelerate  cellular  senescence.  Cell  Cycle. 
2009;8:1896‐1900.  
232. Demidenko  ZN,  Zubova  SG,  Bukreeva  EI,  Pospelov  VA, 
Pospelova  TV,  Blagosklonny  MV.  Rapamycin  decelerates  cellular 
senescence. Cell Cycle. 2009;8:18881895. 
233. Blagosklonny  MV.  Aging‐suppressants:  Cellular  senescence 
(hyperactivation)  and  its  pharmacologic  decleration.  Cell  Cycle. 
2009;8:1883‐1887.  
234. Alimova  IN,  Liu  B,  Fan  Z,  Edgerton  SM,  Dillon  T,  Lind  SE, 
Thor  AD.  Metformin  inhibits  breast  cancer  cell  growth,  colony 
formation  and  induces  cell  cycle  arrest  in  vitro.  Cell  Cycle. 
2009;8:909‐915.  
235. Guenther  GG,  Gdinger  AL.  A  new  take  on  ceramide:  starve 
cells  by  cutting  off  the  nutrient  supply.  Cell  Cycle.  2009;8:1122‐
1126.  
236. Korotchkina  LG,  Demidenko  ZN,  Gudkov  AV,  Blagosklonny 
MV.  Cellular  quiescence  caused by  the  Mdm‐2  inhibitor  nutlin‐
3A. Cell Cycle. 2009;8:3777‐3781.  
237. Shen  J,  Curtis  C,  Tavare  S,  Tower  J.  A  screen  of  apoptosis 
and senescence regulatory genes for life span effects when over‐
expressed in Drosophila. Aging. 2009;1:191‐211.  
238. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers 
WR, Lengauer C, Stegmeier F.  PI3K pathway activation mediates 
resistance  to  MEK  inhibitors  in  KRAS  mutant  cancers.  Cancer 
Res. 2009; 69: 4286‐4293. 
239. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, 
Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, et 
al.   In  vivo  antitumor  activity  of  MEK  and  phosphatidylinositol 3‐
kinase in basal‐like breast cancer models. Clin Cancer Res. 2009; 15: 
4649‐4664. 
240. Laurent‐Puig  P,  Cayre  A,  Manceau  G,  Buc  E,  Bachet  JB, 
Lecomte  T,  Rougier  P,  Lievre  A,  Landi  B,  Boige  V,  Ducreux  M, 
Ychou  M,  et  al.  Analysis  of  PTEN,  BRAF,  and  EGFR  status  in 
determining  benefit  from  cetuximab  therapy  in  wild‐type  KRAS 
metastatic colon cancer. J Clin Oncol. 2009; 27:5924‐5930. 
241. Laurent‐Puig P, Lievre A, Blons H.  Mutations and response 
to epidermal growth factor receptor inhibitors. Clin Cancer Res. 
2009; 15:1133‐1139. 
242. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, 
Côté  JF,  Tomasic  G,  Penna  C,  Ducreux  M,  Rougier  P,  Penault‐
Llorca  F,  Laurent‐Puig  P.  KRAS  mutation  status  is  predictive  of 
response to cetuximab therapy in colorectal cancer. Cancer Res. 
2006; 66:3992‐3995.  

  
www.impactaging.com 

 

 

 

           221                                          AGING, March 2011, Vol.3 No.3

factors 

243. Lièvre  A,  Blons  H,  Laurent‐Puig  P.  Oncogenic  mutations  as 
predictive 
in  colorectal  cancer.  Oncogene.  2010; 
29:3033‐3043. 
244. Pratilas  CA,  Hanrahan  AJ,  Halilovic  E,  Persaud  Y,  Soh  J, 
Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, 
Taylor BS, Pao W, et al. Genetic predictors of MEK dependence 
in non‐small cell lung cancer. Cancer Res. 2008; 68:9375‐9383. 
245. Pratilas  CA,  Solit  DB.  Targeting  the  mitogen‐activated 
protein  kinase  pathway:  physiological  feedback  and  drug 
response. Clin Cancer Res. 2010; 16:3329‐3334 
 
 
 
 
 
 

  
www.impactaging.com 

 

 

 

          222                                          AGING, March 2011, Vol.3 No.3

